CURRICULUM VITAE

Carlos E. Milla, MD

PERSONAL REFERENCES

Birthdate:	September 19, 1961
Birthplace:	Lima, Peru.
Business Address:	Center for Excellence in Pulmonary Biology Department of Pediatrics Stanford University 770 Welch Road Suite 350 Stanford, CA 94304 Phone (650) 723-8325 Fax (650) 723-5201
e-mail Address:	cmilla@stanford.edu
Web Page:	http://Med.Stanford.edu/profiles/Carlos_Milla

HIGH SCHOOL	CEP "La Immaculada", Lima, Peru. 1973 - 1977
COLLEGE	U.P. Cayetano Heredia, School of Sciences and Philosophy, Lima, Peru. April 1978 to March 1980.
MEDICAL SCHOOL	U.P. Cayetano Heredia, School of Medicine, Lima, Peru. April 1980 to March 1986.
Clinical Clerkships:	From July 1984 to March 1986 rotating clerkships in internal medicine, pediatrics, surgery, and obstetrics and gynecology at general hospitals in Lima, Peru.
Research Activities:	From July to September 1985 Tropical Medicine elective in Nauta, Loreto (Peruvian amazon jungle). From April to November 1986 Clinical Research elective at the Renal Unit of A. Loayza Hospital, Lima, Peru.
Graduation:	Physician and surgeon diploma conferred on November 12, 1986.

POSTGRADUATE WORK

1987 to 1988, Clinical Resident at the Instituto de Investigacion Nutricional (Nutrition Research Institute), Lima, Peru.

1988 to 1989, Clinical Research Fellow at the Instituto de Investigacion Nutricional (Nutrition Research Institute), Lima, Peru.

1993 to 1995, Graduate student at the University of Minnesota School of Public Health, Epidemiology major.

1995 - Doctoral student at the Graduate School of the University of Minnesota, Epidemiology major. (Advisor: Russell V. Luepker, MD, MS).

CERTIFICATIONS

Educational Commission for Foreign Medical Graduates, 1989. (Certificate # 409-519-6)
American Board of Pediatrics, 1992.
American Board of Pediatrics, Pulmonology sub-Specialty Board, 1996 (renewed 2003, 2013).

PROFESSIONAL LICENSE

Minnesota Board of Medical Practice, 1992.
Medical Board of California, 2007.

PROFESSIONAL EXPERIENCE

1989 - 1992 Resident in Pediatrics at the Children's Medical Center of Brooklyn, State University of New York Health Sciences Center at Brooklyn.

1992 - 1995 Fellow in Pediatric Pulmonology and Cystic Fibrosis care at the University of Minnesota Hospital and Clinics.

1993 - 2007 Active member of the Professional Staff, Children’s Hospitals and Clinics-Minneapolis, Minneapolis, Minnesota.

1995 - 1996 Postdoctoral Fellow, Pulmonary and Critical Care Division, Department of Pediatrics, University of Minnesota.

1995 - 2007 Active member of the Medical Staff, Fairview-University Medical Center, Minneapolis, Minnesota.

1996 – 1999 Instructor, Pulmonary and Critical Care Division, Department of Pediatrics, University of Minnesota.

1997 - 1999 Co-Director, Cystic Fibrosis Center,

Department of Pediatrics, University of Minnesota

1997 - 2007 Active member of the Medical Staff, Gillette Children's Specialty Healthcare, St. Paul, Minnesota.

1997 - 2007 Active member of the Medical Staff, Saint Paul Regions Hospital (formerly Saint Paul Ramsey Hospital), St. Paul, Minnesota.

1998 - 2007 Active member of the Medical Staff, Hennepin County Medical Center, Minneapolis, Minnesota.

1999 - 2007 Director, The Minnesota Cystic Fibrosis Center,
University of Minnesota Medical School

2000 - 2007 Assistant Professor, Pulmonary and Critical Care Division,
Department of Pediatrics, University of Minnesota.

2003 - 2004 Interim Co-Director, Pulmonary and Critical Care Division,
Department of Pediatrics, University of Minnesota.

2007 - 2017 Associate Professor, Department of Pediatrics, Stanford University.

2007 - Active member of the Medical Staff, Lucile Packard Children's Hospital, Stanford, California.

2007 - Active member of the Medical Staff, Stanford Hospital and Clinics, Stanford, California.

2007 - 2008 Interim Director, Adult Cystic Fibrosis Program, Stanford University.

2008 - 2009 Co-Director, The Stanford Cystic Fibrosis Center at Lucile Packard Children's Hospital, Stanford University, California.

2009 - Director, The Stanford Cystic Fibrosis Center at Lucile Packard Children's Hospital, Stanford University, California.

2016 - Active member of the Medical Staff, Valley Children's Hospital, Department of Pulmonary Medicine, Madera, California.

2016 - Associate Director for Translational Research,
Center for Excellence in Pulmonary Biology
Stanford University

2017 - Professor, Department of Pediatrics, Stanford University

AWARDS

2005	Annalisa Marzotto Endowed Chair in Cystic Fibrosis Care, University of Minnesota Medical School
2005	CF Clinician of the Year Award Chiron Inc.
2007	Crandall Endowed Scholar in Pediatric Pulmonary Medicine, Stanford University School of Medicine
2014	CF Caregiver of the Year Award CF Research Inc.
2016	Distinguished Service Award CF Therapeutics Development Network, Cystic Fibrosis Foundation
2018	Magister in Pediatric Pulmonary Medicine Latin American Society of Pediatric Pulmonology

MEMBERSHIPS

American Academy of Pediatrics.
American Physiological Society (*Elected member*)
American Thoracic Society
European Respiratory Society
European Cystic Fibrosis Society
Society for Pediatric Research (*Elected member*)

PUBLICATIONS

Peer Reviewed Journals:

1. Secord E; **Milla CE**; Shah B. Picture of the month: Ecthyma Gangrenosum secondary to *Pseudomonas aeruginosa*. *Am J Dis Children* 1993, 147:795-796.

2. **Milla CE**; Wielinski C; Warwick WJ. High-strength pancreatic enzymes. *Lancet*, 1994; 343: 599.

3. **Milla CE**; Wielinski,C.; Regelmann, WE. Clinical significance of the recovery of *Aspergillus species* from the respiratory secretions of cystic fibrosis patients. *Pediatr Pulmonol* 1996; 21:6-10. (Editorial comment in: Pediatr Pulmonol 1996;21:1-2).

4. **Milla CE**, Doherty L, Raatz S, Schwarzenberg SJ, Regelmann WE, Moran AM. The glycemic response to varying carbohydrate:fat ratios of dietary supplements in cystic fibrosis. *J Parent Ent Nutr* 1996; 20:182-186.

5. Shreve MR, Johnson SJ, **Milla CE**, Wielinski CL, Regelmann WE. Ribotyping and endonuclease subtyping in the epidemiology of *Burkholderia cepacia. Am J Resp Crit Care Med* 1997; 155:984-989.

6. **Milla CE,** Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. *Chest* 1998; 113:1230-1234. (Editorial comment in: *Chest* 113:1159-1161).

7. Anand IS, Prasad BA, Chugh SS, Rao KRM, Cornfield DN, **Milla CE**, Singh N, Singh S, Selvamurthy W. Effects of inhaled Nitric Oxide and oxygen in high altitude pulmonary edema. *Circulation* 1998; 98:2441-2445.

8. **Milla CE.** Long term effects of aerosolized rhDNase on the pulmonary disease progression of Cystic Fibrosis patients. *Thorax* 1998, 53:1014-1017. (Editorial comment in *Thorax* 53:1003).

9. Cornfield DN, Barbato J, Maynard RC, Guiang S, Derangier RA, **Milla CE**. Randomized controlled trial of low dose inhaled nitric oxide in the treatment of term and near term infants with respiratory failure and pulmonary hypertension. *Pediatrics* 1999; 104:1089-1094.

10. Haddad IY, Ponastalis-Mortari A, Ingbar DH, Yang S, **Milla C**, Blazar B. High levels of preoxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells. A potential mechanism of injury after marrow transplantation. *Am J Resp Cell Mol Biol* 1999; 20 (6):1125-1135.

11. Saqueton CB, Miller RB, Porter VA, **Milla CE**, Cornfield DN. Nitric oxide causes perinatal pulmonary vasodilation through K^+ channel activation and requires intracellular calcium release. *American Journal of Physiology – Lung* 1999; 276:L925-L932.

12. **Milla CE.** Rh DNase in cystic fibrosis. *Lancet* 1999; 354 (9176):428.

13. **Milla CE**, Warwick WJ, Moran AM. Trends in pulmonary function in cystic fibrosis (CF) patients correlate with the results of oral glucose tolerance test at baseline. *Am J Resp Crit Care Med 2000; 162:891-895*.

14. Moran A, **Milla C**, Ducret R, Nair KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. *Diabetes 2001; 50:1336-1343.*

15. Yang S, **Milla CE**, Panostalkis-Moratri A, Ingbar DH, Blazar BR, Haddad IY. Human surfactant protein A suppresses T-cell dependent inflammation and attenuates the manifestations of idiopathic penumonia syndrome in mice. *Am J Resp Cell Mol Biol* 2001; 24(5):527-536.

16. Figueroa V, **Milla CE**, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal Lipid Levels in Cystic Fibrosis. *Am J Clin Nutr* 2002; 75:1005-1011.

17. Moran A, Phillips J, **Milla CE**. Insulin and glucose excursion following pre-meal Insulin lispro or Repaglinide in cystic fibrosis related diabetes. *Diabetes Care* 2001; 24:1706-1710.

18. Yang S, Porter V, Cornfield DN, **Milla C**, Panostalkis-Mortari A, Blazar BR, Haddad IY. Effects of Oxidant Stress on Inflammation and Survival of iNOS Knockout Mice after Marrow Transplantation. *Am J Physiol : Lung* 2001; 281(4):L922-L930.

19. Cornfield DN, Tegtmeyer K, **Milla CE**, Sweeney M. Continuous propofol infusion in 142 critically ill children. *Pediatrics* 2002; 110(6):1177-1181.

20. Yang S, **Milla CE,** Panoskaltsis-Mortari A, Hawgood S, Blazar BR, Haddad IY**.** Surfactant Protein-A (SP-A) decreases lung injury and mortality after Murine Marrow Transplantation. *Am J Respir Cell Mol Biol* 2002; 27: 297-305.

21. Peterson M, Jacobs D, **Milla CE**. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. *Pediatrics* 2003; 112:588-592.

22. Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, **Milla CE**, Moran A. Insulin Glargine Improves Hemoglobin A1c in Children and Adolescents with Poorly Controlled Type 1 Diabetes. *Pediatric Diabetes* 2003; 4:64-69.

23. Cornfield DN, Haddad IY, **Milla CE,** Barbato JE, Park SJ. Safety of inhaled nitric oxide after lung transplantation**.** *J Heart Lung Transpl* 2003; 22:903-907.

24. Haddad IY, **Milla CE**, Yang S, Panoskaltsis-Mortari A, Hawgood S, Lacey DL, Blazar BR. Surfactant Protein A mediates the protective effects of Keratinocyte Growth Factor after experimental marrow transplantation. *Am J Physiol : Lung Cell Mol Physiol* 2003:L602-610.

25. Moss RB, Rodman D, Spencer LT, Aitken M, Zeitlin P, Waltz D, **Milla CE**, Brody A, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated AAV2 Aerosol-mediated CFTR Gene Transfer to the Lungs of Patients with Cystic Fibrosis: A Multicenter, Double-Blind, Placebo-Controlled Trial. *Chest* 2004; 125:509-521.

26. **Milla CE**, Hansen LG, Warwick WJ. High frequency chest compression: Comparison of the second and third generation compression waveforms. *Biomed Instrumentation Technol* 2004; 38:322-327.

27. **Milla CE,** Yang S, Cornfield DN, Brennan ML, Hazen S, Panoskaltsis-Mortari A, Blazar B, Haddad IY. Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. *Am J Physiol : Lung Cell Mol Physiol* 2004; 287(4):L706-714 (Editorial comment in: *Am J Physiol : Lung Cell Mol Physiol* 287:L-704-705).

28. Garner HP, Perentesis JP, Boen JR, Phillips JR, Herron JG, Severson SJ, Kiffmeyer WR, **Milla CE**, Regelmann WE. Circulating Neutrophil Peroxidase Activity Correlates with Sputum Peroxidase Activity, Sputum Production and Airflow Obstruction in Cystic Fibrosis. *J Lab Clin Invest* 2004; 144:127 - 133.

29. Moran A, Basu R, **Milla C**, Jensen MD. Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. *Metabolism* 2004; 11:1467-1472.

30. Eikenberry M, Bartokova H, DeFor T, Haddad IY, Ramsay NKC, Blazar BR, **Milla CE**, Cornfield DN. Natural history of pulmonary complications in children following bone marrow transplantation. *Biol Blood Marrow Transpl* 2005; 11 (1): 56-64.

31. Deshpande AD, White TA, **Milla C**, Walseth TF, Lund FE, Kannan MS. CD38 regulates intracellular calcium and responsiveness to agonists in airway smooth muscle. *Am J Respir Cell Mol Biol* 2005; 32:149-156.

32. Shukla M, Yang S, **Milla C,** Panoskaltsis-Mortari A, Blazar B, Haddad IY. The absence of host tumor necrosis factor receptor 1 attenuates the manifestations of idiopathic pneumonia syndrome. *Am J Physiol : Lung Cell Mol Physiol* 2005; 288:L942-L949.

33. Deterding RR, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin P, **Milla CE**, Marshall B, LaVange L, Engels J, Mathews D, Schaberg A, Williams J, Ramsey B, for the Cystic Fibrosis Foundation Therapeutics Development Network. Safety and Tolerability of Denufosol Tetrasodium Inhalation Solution, a Novel $P2Y_2$ Receptor Agonist: Results of a Phase 1/Phase 2 Multi-Center Study in Mild to Moderate Cystic Fibrosis. *Pediatric Pulmonology* 2005; 39:339-348.

34. **Milla CE**, Billings JL, Moran A. Diabetes is associated with dramatically decreased survival in women but not men with cystic fibrosis. *Diabetes Care* 2005; 28:2141-2144.

35. Perdue DG, Cass OW, **Milla CE**, Dunitz J, Jessurun J, Sharp HL, Schwarzenberg SJ. Hepatolithiasis and Cholangiocarcinoma in Cystic Fibrosis. *Dig Dis Sci* 2007; 52(10):2638-42.

36. Gibson RL, Retsch-Bogart GZ, Oermann C, **Milla CE**, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL**,** Markus R, Burns JL. Microbiology, Safety, and Pharmacokinetics of Aztreonam Lysinate for Inhalation in Patients with Cystic Fibrosis. *Pediatric Pulmonology* 2006; 41(7):656-665.

37. Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, Blazar BR, Orchard PJ, Cornfield DN, Grewal SS, Peters C, Regelmann WE, **Milla CE**, Baker KS. Inflammatory Cytokines and the Development of Pulmonary Complications following Allogeneic Hematopoietic Cell Transplantation in Patients with Inherited Metabolic Storage Disorders. *Biol Bone Marrow Transpl* 2006; 12:430-37.

38. Milla CE, Hansen LG, Warwick WJ. Different frequencies should be prescribed for different High Frequency Chest Compression (HFCC) machines. *Biomed Instrumentation Technol* 2006; 40:319-324.

39. Kempainen R, Williams CB, Hazelwood A, Rubin B, **Milla CE**. Comparison of high frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. *Chest* 2007, 132:1227-1232.

40. Moss RB, **Milla C**, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin H, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of Cystic Fibrosis: a randomized placebo-controlled Phase 2B trial. *Human Gene Therapy* 2007, 18:726–732.

41. Berge JM, Patterson JM, Goetz D, **Milla CE.** Young Adults' Perceptions of living with Cystic Fibrosis during the transition to adulthood: A qualitative investigation. *Families, Sytems and Health* 2007; 25(2):190-203.

42. Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, **Milla CE**, Moran A. Microvascular Complications in Cystic Fibrosis Related Diabetes. *Diabetes Care* 2007; 30(5):1056-1051.

43. Patterson J, Wall M, Berge J, **Milla C**. Gender Differences in Treatment Adherence among Youth Living with Cystic Fibrosis: Development of a New Questionnaire. *J Cystic Fibrosis* 2008; 7:154-164.

44. Zirbes JM, **Milla CE**. Steroid-sparing effect of Omalizumab in the managment of severe Allergic Bronchopulmonary Aspergillosis in children with cystic fibrosis. *Pediatric Pulmonology* 2008; 43:607–610.

45. Paterson JM, Berge J, Wall M, **Milla CE**. Associations of Psychosocial factors with Health Outcomes among youth with Cystic Fibrosis. *Pediatric Pulmonology* 2009; 44:46-53.

46. Harrison AN, Regelmann WE, Zirbes JM, **Milla CE.** Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. *Pediatric Pulmonology* 2009*;* 44:330-339.

47. Orchard PJ, **Milla C**, Braunlin E, DeFor T, Bjoraker K, Blazar BR, Peters C, Wagner J, Tolar J. Pre-transplant factors affecting outcome in Hurler syndrome. *Bone Marrow Transplantation* 2009; 1-9.

48. Kempainen RR, **Milla C**, Dunitz J, Hazelwood A, Williams C, Rubin BK, Billings JL. Comparison of settings used for High Frequency Chest Wall Compression in cystic fibrosis. *Respiratory Care* 2010; 55:695-701.

49. Sabati AA, Kempainen RR, **Milla CE**, Ireland M, Schwarzenberg SJ, Dunitz JM, Kahn KM. Characteristics of Gastroesophageal reflux in adults with cystic fibrosis. *J Cystic Fibrosis* 2010; 9:365-70.

50. Sheridan MB, Wang N, Merlo C, **Milla C,** Borowitz D, Cutting GR, Mogayzel P. Identification of *CFTR* molecular defects in CF patients with one previously identified disease-causing mutation. *Journal of Medical Genetics* 2011; 48:235-241.

51. Olin JT, Burns K, Carson JL, Metjian H, Atkinson JJ, Davis SD, Dell SD, Ferkol TW, **Milla CE**, Olivier KN, Rosenfeld M, Baker B, Leigh MW, Knowles MR, Sagel SD, for the Genetic Disorders of Mucociliary Clearance Consortium. Diagnsotic yield of nasal scrape biopsies in primary ciliary dyskinesia: A multicenter experience. *Pediatr Pulmonol* 2011; 46:483-488.

52. Coates AC, Mehan R, **Milla** CE. Dyspnea in a Patient With Raynaud's Phenomenon: The Uncovering of Interstitial Lung Disease. *Pediatr Pulmonol* 2012; 47:926-927.

53. Kempainen RR, Sajan J, Pylkas AM, Dunitz JM, Rimell FL, **Milla CE**. Lack of Effect of Endoscopic Sinus Surgery on the Pulmonary Status of Adults with Cystic Fibrosis. *Otolaryngology - Head and Neck Surgery* 2012; 147:557-562.

54. Blainey PC, **Milla CE***, Cornfield DN*, Quake SR*. Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. *Science Translational Medicine* 2012; 4:153ra130. (*Co-Senior authorship)

55. Knowles MR, Leigh MW, Ostrowski LE, Huang L, Carson JL, Hazucha MJ, Yin W, Berg JS, Davis SDD, Dell SD, Ferkol TW, Rosenfeld M, Sagel SD, **Milla CE**, Olivier KN, Turner EH, Lewis AP, Bamshad MJ, Nickerson DA, Shendure J, Zariwala MA and the Genetic Disorders of Mucociliary Clearance Consortium. Exome Sequencing identifies CCDC114 as a Novel Gene causing Primary Ciliary Dyskinesia associated with Defective Outer Dynein Arms. *Am J Human Genetics* 2013; 92:1-8.

56. Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, **Milla** C, Starner T, Weiner DJ, Lee PS, Ratjen F. Lung clearance index to evaluate clinical response to the CFTR potentiator ivacaftor in cystic fibrosis patients with the *G551D-CFTR* mutation and preserved spirometry. *Lancet Respiratory Medicine* 2013; 1:630-638.

57. Wine JJ, Char J, Chen J, Cho HJ, Dunn C, Frisbee E, Joo NS, Wolfe M, **Milla CE**, Modlin S, Park IH, Thomas E, Tran K, Verma R. In vivo readout of CFTR function: Ratiometric Measurement of CFTR-Dependent Secretion by Individual, Identifiable Human Sweat Glands. *PLoS ONE* 2013; 8(10): e77114.

58. Sun W, Araci Z, Inayathullah M, Manickam S, Zhang X, Bruce MA, Marinkovich MP, Lane A, **Milla C**, Rajadas J, Butte MJ. Polyvinylpyrrolidone microneedles enable delivery of intact proteins for diagnostic and therapeutic applications. *Acta Biomaterialia* 2013; 9:7767-7774.

59. Konstan MW, Borowitz D, Mayer-Hamblett N, **Milla C**, Hendeles L, Murray S, Kronmal RA, Casey S, Rose L, Folger-Bruce K, Morgan WJ, Ramsey BW. Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis. *Clinical Investigation* 2013; 3:731-41.

60. Prach L, Koepke R, Kharrazi M, Keiles S, Salinas DB, Reyes MC, Pian M, Opsimos H, Otsuka KN, Hardy KA, **Milla CE**, Zirbes JM, Chipps B, O'Bra S, Saeed MM, Sudhakar R, Lehto S, Nielson D, Shay GF, Seastrand M, Jhawar S, Nickerson B, Landon C, Thompson A, Nussbaum E, Chin T, Wojtczak H; California Cystic Fibrosis Newborn Screening Consortium. Novel CFTR variants identified during the first three years of cystic fibrosis newborn screening in California. *J Mol Diagn* 2013; 15:710.

61. Austin-Tse C, Halbritter J, Zariwala MA, Gilberti RM, Gee HY, Hellman N, Pathak N, Liu Y, Panizzi JR, Patel-King RS, Tritschler D, Bower R, O'Toole E, Porath J, Hurd TW, Chaki M, Diaz KA, Kohl S, Lovric S, Hwang DY, Braun DA, Schueler M, Airik R, Otto EA, Leigh MW, Noone PG, Carson JL, Davis SD, Pittman JE, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Dell SD, Rosenfled M, **Milla CE**, Loges NT, Omran H, Porter ME, King SM, Knowles MR, Drummond IA, Hildebrandt F. A zebrafish ciliopathy screen reveals *C21ORF59*

and *CCDC65* 1 defects as causing human primary ciliary dyskinesia. *Am J Human Genetics* 2013; 93:672-86.

62. Milla CE, Chmiel JF, Accurso FJ, McCoy KS, Billings JL, Atkinson JJ, Liou TG, Clancey JP, Pilewski JM, Acton JD, Yarranton G, Leff JA. Anti-PCRv antibody in cystic fibrosis: A novel approach targeting *Pseudomonas aeruginosa* airway infection. *Pediatric Pulmonology* 2014; 49:650-8.

63. Leigh MW, Hazucha MJ, Chawla KK, Baker BR, Shapiro AJ, Brown DE, LaVange LM, Horton BJ, Qaqish B, Carson JL, Davis SD, Dell SD, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Rosenfeld M, **Milla C**, Lee HS, Krischer J, Zariwala MA, Knowles MR, and the Genetic Disorders of Mucociliary Clearance Consortium. Standardizing Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. *Ann Am Thorac Soc* 2013; 10:574-81.

64. Shapiro AJ, Davis SD, Ferkol TW, Dell SD, Rosenfeld M, Olivier KN, Sagel SD, **Milla C,** Zariwala MA, Wolf W, Carson JL, Hazucha MJ, Burns K, Robinson B, Knowles MR, Leigh MW and the Genetic Disorders of Mucociliary Clearance Consortium. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia: Insights into situs ambiguous and heterotaxy. *CHEST* 2014; 146:1176-86.

65. Knowles MR, Ostrowski LE, Leigh MW, Sears PR, Davis SD, Wolf WE, Hazucha M, Carson JL, Olivier KN, Sagel SD, Rosenfeld M, Ferko, TW, Dell SD, **Milla CE**, Randell SH, Yim W, Sannuti A, Metjian HM, Noone PG, Noone P, Olson CA, Patrone M, Dang H, GDMCC Team, NHLBI GO Exome sequencing project, Lee HS, Hurd T, Gee HY, Otto EA, Halbritter J, Kircher M, Krischer J, Bamshad MJ, Nickerson DA, Hildebrandt F, Schedure J, Zariwala M. Mutations in RSPH1 Cause Primary Ciliary Dyskinesia with unique Clinical and Ciliary Phenotype. *Am J Resp Crit Care Med* 2014; 189:707-717.

66. Char JE, Wolfe MH, Cho H, Park IH, Jeong JH, Frisbee E, Dunn C, Davies Z, **Milla CE**, Moss RB, Thomas EAC, Wine JJ. A little CFTR goes a long way: CFTR-Dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking Ivacaftor. *PLoS ONE* 2014; 9(2):e88564.

67. Hilgendorff A, Parai K, Ertsey R, Navarro E, Jain N, Carandang F, Peterson J, Mokres L, **Milla C**, Preuss S, Alcazar MA, Khan S, Masumi J, Ferreira-Tojais N, Starcher B, Rabinovitch M, Bland R. Lung matrix and vascular remodeling in mechanically ventilated elastin haplo-insufficient (Eln+/−) newborn mice. *Am J Physiol Lung Cell Mol Physiol* 2015; 308:L464-78.

68. Davis SD, Ferkol TW, Rosenfeld M, Lee HS, Dell SD, SD, **Milla C**, Zariwala MA, Pittman JE, Shapiro AJ, Carson JL, Krischer JP, Hazucha MJ, Cooper ML, Knowles MR, Leigh MW. Clinical Features of Childhood Primary Ciliary

Dyskinesia By Genotype and Ultrastructural Phenotype. *Am J Resp Crit Care Med* 2015; 191 (3): 316-324.

69. Subbarao PJ, **Milla C**, Aurora P, PhD, Davies JC, Davis SD,Hall GL, Heltshe S, Latzin P, Lindblad A , Pittman JE, Robinson PD, Rosenfeld M, Singer F, Starner TD, Ratjen F, Morgan W.Multiple breath washout as a lung function test in cystic fibrosis. A Cystic Fibrosis Foundation workshop report. *Ann Am Thorac Soc* 2015; 6:932-9.

70. Ramsi MA, Henry M, **Milla CE**, Cornfield DN. Inhaled Beta2-agonist therapy increases functional residual capacity in mechanically ventilated children with respiratory failure. *Ped Crit Care Med* 2015; 16:e189-193.

71. Buu M, Sanders L, Mayo J , **Milla C**, Wise P. Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with CF in California. *CHEST* 2016; 149(2):380-389.

72. Leigh MW, Ferkol TW, Davis SD, Lee HS, Rosenfeld M, Dell SD, Sagel SD, **Milla C**, Olivier KN, Sullivan KM, Zariwala MA, Pittman JE, Shapiro AJ, Carson JL, Krischer J, Hazucha M, Knowles MR. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. *Ann Am Thorac Soc* 2016; 13:1305–1313.

73. Macmurdo CF, Wooderchack-Donahue W, Bayrack-Toydemir P, Le J, Wallenstein MB, **Milla C**, Teng JMC, Bernstein JA, Stevenson DA. RASA1 Somatic Mutation and Variable Expressivity in Capillary Malformation/Arteriovenous Malformation (CM/AVM) Syndrome. *Am J Med Genet* 2016; 170:1450-4.

74. Vladar EK, Nayak J, **Milla C**, Axelrod J. Airway epithelial homeostasis and planar cell polarity signaling depend on multiciliated cell differentiation. *J Clin Invest – Insight* 2016; 1(13):e88027.

75. Kim J, Farahmand M, Dunn C, Davies Z, Frisbee E, **Milla C**, Wine JJ. Evaporimeter and bubble-imaging measures of sweat gland secretion rates. *PLoS ONE,* 2016; 11(10): e0165254.

76. **Milla C**, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M. Lumacaftor/Ivacaftor in patients Aged 6-11 years with Cystic Fibrosis homozygous for F508del-CFTR. *Am J Resp Crit Care Med* 2017; 195:912-920.

77. Char J., Dunn C, Davies Z, **Milla C**, Moss R, Wine J. The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements. *PLoS ONE*, 2017; 12(4): e0175486.

78. Kao J, Zirbes JM, Conrad CK, **Milla CE**. Lung clearance index is sensitive to small airway disease in children post-lung transplant. *J Heart Lung Transpl* 2017; 36:980-4.

79. Lechtzin N, Mayer-Hamblett N, West N, Allgood S, Wilhelm E, Khan U, Aitken ML, Ramsey BW, Boyle MP, Mogayzel Jr PJ, Gibson RL, Orenstein D, **Milla C**, Clancy JP, Antony V, Goss CH. Home monitoring in CF to identify and treat acute pulmonary exacerbations: eICE Study results. *Am J Resp Crit Care Med* 2017; 196:1144-51.

80. Emaminejad S, Gao W, Wu E, Davies Z, Nyein HYY, Challa S, Ryan S, Fahad HM, Chen K, Shahpar Z, Talebi S, **Milla C***, Javey A*, Davis RW*. Autonomous Sweat Extraction and Analysis Applied to Cystic Fibrosis and Glucose Monitoring Using a Fully-Integrated Wearable Platform. *Proc Natnl Acad Sci* 2017, 114:4625-4630. (* Drs. Milla, Javey and Davis shared senior authorship and are co-corresponding authors).

81. Ratjen F, Tian S, Marigowda G, Hug C, Huang X, Stanojevic S, **Milla C,** Robinson P, Waltz D, Davies JC. Efficacy and safety of lumacaftor/ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised placebo-controlled phase 3 trial. *Lancet Resp Med* 2017; 5:557-567.

82. Iturralde E, Barley RC, Bensen R, Christofferson M, Hanes SJ, Maahs DM, **Milla C**, Naranjo D, Shah AC, Tanenbaum MT, Veeravalli S, Park KT, Hood KK. Implementation of Depression and Global Health Screening in Three Pediatric Subspecialty Clinics. *Journal of Adolescent Health* 2017; 61:591-598.

83. Kim J, Davies Z, Dunn C, Wine JJ, **Milla C**. Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles. *J Cystic Fibrosis* 2018; 17:179-85.

84. Alcazar MA, Kaschwich M, Ertsey R, Preuss S, **Milla C**, Mujahid S, Masumi J, Khan S, Mokres LM, Tian L, Mohr J, Hirani DV, Rabinovitch M, Bland RD. Elafin treatment rescues EGFR-Klf4 signaling and lung cell survival in ventilated newborn mice. *Am J Respir Cell Mol Biol* 2018; 59 (5): 623–34.

85. Kim J, Farahmand M, Dunn C, **Milla CE**, Imari-Horii R, Thomas EAC, Moss RB2, Wine JJ. Sweat rate analysis of ivacaftor potentiation of CFTR in healthy humans. *Sci Reports* 2018; 8: 16233, 1-10.

86. Jain R, Beckett VV, Konstan MW, Accurso FJ, Burns, JL, Mayer-Hamblett N, **Milla C**, VanDevanter DR, Chmiel JF. KB001-A, a novel anti-inflammatory found to be safe and well tolerated in cystic fibrosis patients infected with *Pseudomonas aeruginosa*. *J Cystic Fibrosis* 2018;17(4):484-491.

87. Chi DL, Rosenfeld M, Mancl L, Chung WO, Presland RB, Sarvas E, Rothen M, Alkhateeb A, McNamara S, Genatossio A, Virella-Lowell I, **Milla C**, Scott JA. Age-related heterogeneity in dental caries and associated risk factors in individuals with cystic fibrosis ages 6–20 years: A pilot study. *J Cystic Fibrosis* 2018; 17: 747 - 759.

88. Davis S, Rosenfeld M, Lee HS, Ferkol T, Sagel S, Dell S, **Milla C**, Pittman J, Shapiro A, Sullivan K, Nykamp K, Krischer J, Zariwala M, Knowles M, Leigh M. Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. *Am J Resp Crit Care Med* 2019; 199(2):190-198.

89. Burgener E, Sweere J, Bach M, Secor P, Tian L, Nedelec L, Bollyky P, **Milla C**. Pf bacteriophage are associated with chronic Pseudomonas lung infections and increased antibiotic resistance in cystic fibrosis. *Sci Transl Med* 2019; 11, eaau9748.

90. Stevens EM, Vladar EK, Alanin MC, Christensen ST, von Buchwald C, **Milla C.** The localization of the Intraflagellar Transport Protein IFT88 is disrupted in Cystic Fibrosis. *In Press, Am J Respir Cell Mol Biol.*

91. Zhou Z, Alvarez D, **Milla C**, Zare R. Proof of Concept for Accurate Identification of Cystic Fibrosis from Perspiration Samples. *In Press, Proc Natnl Acad Sci.*

92. Vaidyanathan S, Salahudeen A, Sellers ZM, Bravo DT, Choi SS, Batish A, Le A, Kaushik MP, Galper N, Lee C, Bao G, Chang EH, Wine JJ, **Milla CE,** Desai T, Nayak J, Kuo CJ, Porteus M. Highly Efficient Repair of the ΔF508 Mutation in Airway Stem Cells of Cystic Fibrosis Patients with Functional Rescue of the Differentiated Epithelia. *In Press, Cell - Stem Cell.*

93. Malkovskiy A, Yacob AA, Dunn CE, Zirbes JM, Ryan SP, Bollyky PL, Rajadas J, **Milla CE**. Salivary hypothiocyanate as a novel biomarker of Cystic Fibrosis Transmembrane Regulator function. *In Press, Analytical Chemistry.*

94. Sellers ZM, Lee LW, Barth RA, **Milla CE.** New Algorithm for the Integration of Ultrasound into Cystic Fibrosis Liver Disease Screening. *In Press, JPGN.*

95. Sellers ZM, Levitte S, Barth RA, **Milla CE.** Clinical Use of Ultrasound Shear Wave and Magnetic Resonance Elastography in the Detection of Cystic Fibrosis Liver Disease in Children. *In review, JPGN*.

96. Lin S, Wang B, Zhao Y, Shih R, Cheng X, Yu W, Hojaiji H, Lin H, Hoffman C, Ly D, Tan J, Chen Y, Di Carlo D, **Milla CE**, Emaminejad S. Natural Perspiration Sampling and In-Situ Electrochemical Analysis with Hydrogel Micropatches for User-Identifiable and Wireless Chemo/bio-sensing. *In review, ACS Sensors.*

Reviews:

1. **Milla CE**. What is a Cystic Fibrosis pulmonary exacerbation? *Pediatr Pulmonol* 2003; S25: 146-147.

2. Kotlikoff MI, Kannan MS, Solway J, Deng KY, Deshpande DA, Dowell M, Feldman M, Green KS, Ji G, Johnston R, Lakser O, Lee J, Lund FE, **Milla C**, Mitchell RW, Nakai J, Rishniw M, Walseth TF, White TA, Wilson J, Xin HB, Woodruff PG. Methodologic advancements in the study of airway smooth muscle. *J Allergy Clin Immunol* 2004; 114:S18-31.

3. **Milla CE.** Association of nutritional status and pulmonary function in children with Cystic Fibrosis. *Curr Opin Pulm Med* 2004; 10:505 - 509.

4. Ferkol T, Rosenfeld M, **Milla CE**. Cystic Fibrosis pulmonary exacerbations. *Journal of Pediatrics* 2006; 148:259-264.

5. **Milla CE**. Cystic Fibrosis Related Diabetes. *Current Medical Literature – Diabetes* 2006; 23:33-38.

6. Zirbes JM, **Milla CE.** Cystic Fibrosis Related Diabetes. *Paediatric Respiratory Reviews* 2009; 10(3):118-123.

7. Matel J, **Milla C.** Nutrition in cystic fibrosis. *Seminars in Respiratory and Critical Care Medicine* 2009; 30 (5)579-586.

8. **Milla CE**. Diagnostic challenges in a screened population: The California CF newborn screening program experience. *Pediatr Pulmonol* 2011; S34: 130-131.

9. Zirbes JM, **Milla CE.** Pulmonary manifestations of endocrinologic diseases. *Paediatric Respiratory Reviews* 2012; 12(1):23-8.

10. **Milla CE**. Antibody-based antibacterial agents: an emerging option. *Drugs of the Future* 2012; 37 (1):33-43.

11. **Milla CE.** Cystic Fibrosis in the era of genomic medicine. *Current Opinion in Pediatrics* 2013; 25:323-328.

12. **Milla CE,** Moss RB. Recent advances in Cystic Fibrosis. *Current Opinion in Pediatrics* 2015; 27: 317-24.

13. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, Margaret Rosenfeld M, Olivier KN, **Milla C**, Daniel SJ, Kimple AJ, Manion M, Knowles MR Leigh mw for the Genetic Disorders of Mucociliary Clearance Consortium. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD

foundation consensus recommendations based on state of the art review. *Pediatric Pulmonology* 2016*;* 51:115-132.

14. **Milla C.** The Evolving Spectrum of Ciliopathies and Respiratory Disease. *Current Opinion in Pediatrics* 2016; 28:339-347.

15. Kharrazi M, **Milla C**, Wine JJ. Controversies and issues surrounding sweat chloride testing. *Lancet Respiratory Medicine* 2016; 4:606-607.

16. Ren CL, Borowitz DS, Gonska T, Howenstine M, Levy H, Massie J, **Milla C**, Munck A, Southern KW. CFTR-Related Metabolic Syndrome (CRMS) and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID). *J Pediatr* 2017, 181S:S45-S51.

17. Schwarz C, Hartl, D, Eickmeier O, Hector A, Benden C, Durieu I, Sole A, Gartner S, **Milla CE**, Barry PJ. Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. *Mycopathologia* 2018, 183:21-32.

18. **Milla CE.** New developments in the assessment of lung function in CF patients. *Pediatr Pulmonol* 2018; 53(S2):138-140.

19. Robinson PD, Latzin P, Ramsey KA, Stanojevic S, Aurora P, Davis SD, Gappa M, Hall GL, Horsley A, Jensen R, Lum S, **Milla C**, Nielsen KG, Pittman J, Rosenfeld M, Singer F, Subbarao P, Gustafsson P, Ratjen F. Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement: Executive Summary. *Am J Resp Crit Care Med* 2018*;* 197(5):e1-e19.

20. Shapiro AJ, Davis SD, Polineni D, Manion M, Rosenfeld M, Dell SD, Chilvers MA, Ferkol TW, Zariwala MA, Sagel SD, Josephson M, Morgan L, Yilmaz O, Olivier KN, **Milla C**, Pittman JE, Daniels LA, Jones MH, Janahi IA, Ware SM, Daniel SJ, Cooper ML, Nogee LM, Anton B, Eastvold T, Ehrne L, Guadagno E, Knowles MR, Leigh MW, Lavergne V. Diagnosis of Primary Ciliary Dyskinesia: An Official ATS Clinical Practice Guideline. *Am J Resp Crit Care Med* 2018; 197(12):e24-e39.

Book Chapters:

1. **Milla CE.** Nutrition and lung disease in cystic fibrosis. In: Whittaker LA Ed., Cystic Fibrosis. *Clin Chest Med* 2007; 28:319-330.

2. **Milla CE.** Endocrine and metabolic disease. In: Turcios N and Fink R; Pulmonary Manifestations of Pediatric Systemic Disease. Elsevier, Philadelphia, PA 2009.

Editorials:

1. **Milla CE**. Editorial: Allergic bronchopulmonary aspergillosis and cystic fibrosis. *Pediatric Pulmonology 1999, 27:71-73*.

2. Moran AM, **Milla CE**. Editorial. Abnormal glucose tolerance in cystic fibrosis: Why should patients be screened? *J Pediatrics* 2003; 142:97-99.

3. **Milla C. E.,** Billings J., Moran A. Of Genes and Men: The Alternative View of Sex Differences in Cystic Fibrosis. Diabetes Care 2006; 29:180.

4. O'Sullivan BP, Orenstein DM, **Milla CE.** Pricing for orphan drugs: will the market bear what society cannot? *JAMA* 2013; 310:1343-1344.

5. **Milla CE.** Novel therapeutics for Cystic Fibrosis: What does the future hold? *Clinical Investigation* 2014; 4: 297-299.

6. Buu M**, Milla CE.** Tear Down this Wall: Diversity and Disparities in Cystic Fibrosis. *Am J Resp Crit Care Med*, 2018; 198(8):983-984.

Abstracts:

1. **Milla CE**; Regelmann WE; Wielinski C. The distribution of the ΔF508 mutation in a group of deceased Cystic Fibrosis patients. *Am Rev Respir Dis* 1993; 147(4): A579.

2. **Milla CE**; Regelmann WE; Wielinski C. Comparison of the decline in pulmonary function in deceased cystic fibrosis patients homozygous for the ΔF508 mutation versus compound heterozygotes for the ΔF508 mutation. *Am Rev Respir Dis* 1993; 147(4): A464.

3. **Milla CE**; Wielinski C; Warwick WJ. Distal intestinal obstruction syndrome (DIOS) and association with pancreatic enzyme supplementation in a cohort of cystic fibrosis patients. *Pharmacoepidemiology* 1994; 3(S1):S30. (Presented at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden, 1994).

4. Wielinski C; **Milla CE**; Warwick WJ. Management effect due to the introduction of high potency pancreatic enzyme capsules (greater than 22,000 lipase units/capsule) for treatment of pancreatic insufficiency in cystic fibrosis. *Pharmacoepidemiology* 1994; 3(S1):S30. (Presented at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden, 1994).

5. **Milla CE**; Wielinski C, Warwick WJ. Survival analysis of a group of Cystic Fibrosis patients with FEV_1 below 30% of predicted. *Am J Resp Crit Care Med* 1994, 149:676.

6. **Milla CE**; Wielinski C, Regelmann WE. Clinical significance of *Aspergillus sp.* in CF respiratory secretions. *Pediatric Pulmonol* 1994; S10: 257.

7. **Milla CE**; Wielinski C, Zirbes JM, Warwick WJ. Clinical characteristics of cystic fibrosis (CF) patients waiting for lung transplantation. *Pediatric Pulmonol* 1994; S10: 270.

8. Warwick WJ, **Milla CE**; Wielinski C. Epidemiologic investigation of the incidence of gastrointestinal problems in a cohort of CF patients and its relation to the use of high strength pancreatic supplements. *Pediatric Pulmonol* 1995; 19:85-86.

9. **Milla CE**, Regelmann WE. Development of a new method to study intraphagocytic bacterial killing. *Pediatric Research* 1995, 37(p2):184A.

10. **Milla CE**, Wielinski CL, Warwick WJ. Potential usefulness of cyclosporine as an antiinflammatory drug in cystic fibrosis patients with advanced lung disease. *Am Journal Resp Crit Care Med* 1995, 151 (pt 2 of 2): A249.

11. Shreve MR, Johnson S, **Milla CE**, Wielinski C, Regelmann WE. Polymerase chain reaction based ribotyping and endonuclease subtyping are useful in determining *Burkholderia cepacia* transmission and blood stream invasion in cystic fibrosis patients. *Am Journal Resp Crit Care Med* 1995, 151 (pt 2 of 2): A740.

12. **Milla CE**, Doherty L, Raatz S, Schwartzenberg SJ, Regelmann WE, Moran A. Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis patients with severe pulmonary function impairment. *Pediatric Pulmonol* 1995; S12:261.

13. **Milla CE**, Wielinski CL, Jacobs D, Warwick WJ. Rate of decline in FEV_1 as a prognostic indicator among cystic fibrosis patients with different degrees of lung function impairment. *Am Journal Resp Crit Care Med* 1996, 153 (pt 2 of 2): A71.

14. Shreve MR, Johnson S, **Milla CE**, Wielinski C, Regelmann WE. Ribotyping and endonuclease subtyping in the epidemiology of *Burkholderia cepacia Am Journal Resp Crit Care Med* 1996, 153 (pt 2 of 2): A706.

15. **Milla CE**, Hite SH, Warwick WJ. Lung volume measurements in infants and young children with cystic fibrosis by a radiographic method. *Am Journal Resp Crit Care Med* 1997, 155 (pt 2 of 2): A646.

16. Shreve MR, **Milla CE,** Johnson AJ, Regelmann WE. Suitability of techniques of P. aeruginosa DNA fingerprinting to determine risk of acquisition in cystic fibrosis. *Pediatric Research* 1997, 41(pt2):A.

17. Haddad IY, Ponoskaltis-Mortari A, Ingbar D, **Milla CE**, Blazar B. Allogeneic T cells activate alveolar macrophages (AM) to produce autotoxic levels of Nitric Oxide during bone marrow transplantation (BMT). *Am Journal Resp Crit Care Med* 1998, 157 (3, pt 2 of 2): A272.

18. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in cystic fibrosis (CF) patients correlate with the results of oral glucose tolerance test at baseline. *Pediatr Pulmonol* 1998, S17:369.

19. Milla CE, Warwick WJ. Pulmonary function in infants with cystic fibrosis at the time of diagnosis and throughout the first 2 years of life. *Pediatr Pulmonol* 1998, S17:332.

20. Warwick WJ; Hansen LG; **Milla CE**. The improved sweat test, i.e. the Gibson-Cooke sweat test that is quantitative with 5 mg of sweat. *Pediatr Pulmonol* 1998, S17:698.

21. Milla CE, Regelmann WE, Severson SJ, Warwick WJ. Risk factors associated with FEV_1 decline in cystic fibrosis (CF) patients with normal pulmonary function. *Pediatric Research* 1999, 45(4, pt. 2 of 2):353A.

22. Milla CE, Moran AM. Insulin Production at baseline influences the rate of decline in FEV_1 in cystic fibrosis patients without fasting hyperglycemia. *Pediatr Pulmonol* 1999; S19:305.

23. Zirbes JM, **Milla CE**. Lung transplantation for cystic fibrosis: ten year experience. *Pediatr Pulmonol* 1999; S19:294.

24. Moran AM, **Milla CE**, Ducret R, Nair S. Protein metabolism in clinically stable, well-nourished adult cystic fibrosis patients with abnormal glucose tolerance. . *Pediatr Pulmonol* 1999; S19:305.

25. Milla CE, Jacobs DR, Warwick WJ. Trends in FEV_1 and Body Mass Index (BMI) are strong predictors of death from pulmonary complications in patients with cystic fibrosis. *Pediatr Pulmonol* 1999; S19:338.

26. Milla CE, Hansen LG, Warwick WJ. Selection of frequencies for high frequency chest wall oscillation (HFCWO) in patients with cystic fibrosis (CF) must be individualized. *Am Journal Resp Crit Care Med* 2000, 161 (3, pt 2 of 2): A74.

27. Meyer CL, Adams A, Stone M, Polley C, **Milla C**. Measuring and predicting FRC and TLC in non-cooperative pediatric candidates for scoliosis correction surgery. (American Association for Respiratory Care International Respiratory Congress, 2000).

28. Warwick WJ, **Milla CE**. Cystic fibrosis after age 40. (23rd European Cystic Fibrosis Conference, Stockholm, Sweden, 2000).

29. Billings J, Dunitz JM, Warwick WJ, **Milla CE**. Long term survival of women with cystic fibrosis following pregnancy. *Pediatr Pulmonol* 2000; S20:312

30. Garner HP, Boen J, Perentesis J, Severson S, **Milla CE**, Regelmann WE. Variability in Myeloperoxidase activity and protein content in circulating neutrophils from cystic fibrosis patients. *Pediatr Pulmonol* 2000; S20:262.

31. Figueroa V, Schwarzenberg SJ, **Milla CE**, Moran A. Isolated hypertriglyceridemia is Common in CF. *Pediatr Pulmonol* 2000; S20:325.

32. Milla CE, Adams A, Koop S, McCarty K, Polley K Meyer CL. Mechanical work of breathing in neurologically involved children with scoliosis. *Am Journal Resp Crit Care Med* 2001, 163 (5): A373.

33. Meyer C, Adams A, Koop S, McCarty K, Stone M, Marini J, **Milla C.** Lung restriction with scoliosis in pediatric candidates for corrective surgery. *Am Journal Resp Crit Care Med* 2001, 163 (5): A372.

34. Milla CE, Baker KS, Ramsay NKC, Cornfield DN. Changes in pulmonary function after bone marrow transplantation in children. *Am Journal Resp Crit Care Med* 2001, 163 (5): A856.

35. Hansen LG, Warwick WJ, Brown IV, **Milla CE**. A quantitative pilocarpine iontophoresis sweat chloride test in less than 30 minutes. (24th European Cystic Fibrosis Conference, 2001).

36. Warwick WJ, Hansen LG, **Milla CE**, Webe A, Seidlitz B, Locher M. The third generation waveform for airway clearance using high frequency chest wall oscillation (HFCWO) therapy. (24th European Cystic Fibrosis Conference, 2001).

37. Milla CE, Phillips J, Moran A. Insulin and Glucose Excursion Following Pre-Meal Insulin Lispro or Repaglinide in CFRD. *Pediatr Pulmonol* 2001; S22: 335.

38. Billings J, **Milla CE**. Risk factors for pneumothorax and prognostic implications in CF. *Pediatr Pulmonol* 2001; S22: 323.

39. Peterson M, Jacobs D, **Milla CE**. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis. *Pediatr Pulmonol* 2001; S22: 327.

40. **Milla C E**, Moran A. M.Risk Of Mortality In Cystic Fibrosis (CF) Patients With Diabetes Is Associated With Gender And FEV1 At The Time Of Onset Of Diabetes. *Am Journal Resp Crit Care Med* 2002, 165 (8): A283.

41. Phillips J, Regelmann WE, **Milla CE**. A new minimally invasive technique to place agarose beads in the murine airway. *Am Journal Resp Crit Care Med* 2002, 165 (8): A509.

42. Peters C, Orchard PJ, Grewal SS, Shapiro EG, Ziegler RS, Charnas LR, Lockman LA, **Milla CE**, Dusenbery KE, Ahrens MJ, Davies SM, Johnson K, Abel SL, Ramsay NKC, Krivit W. Successful Long-term Treatment of alpha-Mannosidosis By Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) (44th American Society of Hematology meeting).

43. Warwick WJ, **Milla CE.** Cystic Fibrosis: Soon to be a geriatric problem. (25th European Cystic Fibrosis Conference, Genoa, Italy, 2002).

44. Moss R, Aitken M, Clancy J, **Milla CE**, Rodman D, Spencer T, Waltz D, Zeitlin P, Zoe D, Hamblett N, Johnson C, Pederson P, Carlin J. A Multicenter, Double-blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF in Cystic Fibrosis Patients with Mild Lung Disease. *Pediatr Pulmonol* 2002; S24:250.

45. Kingsley DW, Herron J, Haddad IY, **Milla CE**. Burkholderia cepacia (BC) induces greater airway obstruction than Pseudomonas aeruginosa (PA) in a mouse model of chronic bronchial infection. *Am Journal Resp Crit Care Med* 2003, 167 (7): A916.

46. Shukla MA, Yang S, **Milla CE**, Panoskaltsis-Mortari A, Blazar BR, Haddad IY. Mechanisms of decreased lung injury in TNF receptor 1 (P55)-Deficient mice after allogeneic marrow transplantation. *Am Journal Resp Crit Care Med* 2003, 167 (7): A730.

47. Haddad IY, **Milla CE**, Hawgood S, Yang S, Panoskaltsis-Mortari A, Blazar BR. Surfactant protein A (SPA) is the mediator responsible for the pulmonary anti-inflammatory effects of keratinocyte growth factor after allogeneic marrow transplantation. *Am Journal Resp Crit Care Med* 2003, 167 (7): A935.

48. Kharbanda S, Baker S, Orchard PJ, Grewal SS, Ramsay NKC, Abel SL, **Milla CE**, Regelmann WE, Haddad IY, Panoskaltsis-Moratri A, Cornfield DN, Krivit W, Peters C. Bronchoalveolar lavage (BAL) before hematopoietic cell transplant

(HCT) identifies infectious agents in pediatric metabolic storage disorder (MSD) patients. *(Presented at the 2003 Pediatric Academic Societies' Meeting, Seattle).*

49. Peterson ML, **Milla CE**. Growth potential as assessed by mid-parental height and pulmonary function in children with Cystic Fibrosis. *Pediatr Pulmonol* 2003; S25: 348.

50. Milla CE, Moran AM. Females with CF Related Diabetes are at higher risk for early mortality. *Pediatr Pulmonol* 2003; S25:352.

51. Dunitz JD, Warwick WJ, **Milla CE**. Clinical Characteristics of Cystic Fibrosis Patients Living Beyond Age 40. *Pediatr Pulmonol* 2003; S25: 336.

52. Billings JL, Moran AM, **Milla CE**. A menstrual cycle questionnaire in women with Cystic Fibrosis. *Pediatr Pulmonol* 2003; S25: 352.

53. Warwick WJ, **Milla CE**, Dodge JA. A life table estimate of CF survival after age 40 suggests that these patients will have a 54% chance of surviving to age 60. *J Cystic Fibr* 2004; 3 (Suppl. 1):S121.

54. Dodge JA, **Milla CE**, Warwick WJ. A Study of Cystic Fibrosis (CF) Associated Diseases of Aging.. *J Cystic Fibr* 2004; 3 (Suppl. 1):S122.

55. Patterson JM, Wall M, **Milla CE**. Behavioral Risk Factors Associated with Morbidity Among Youth with Cystic Fibrosis. *(Presented at the 2004 SPP National Conference on Child Health Psychology).*

56. McKee E, Schissel K, Kleinschmidt T, **Milla C**. Implementation of an interdisciplinary management model for malnutrition in children with CF. *Pediatr Pulmonol* 2004; S27: 348.

57. Gibson RL, Retsch-Bogart G, Ahrens R, Clancy J, Daines C, **Milla C**, Oermann C, Pilewski J. Safety and tolerability of Aztreonam for inhalation in cystic fibrosis patients.*Pediatr Pulmonol* 2004; S27: 348.

58. Moss RB, **Milla C**, Colombo J, Clancy JP, Zeitlin P, Spencer T, Accurso F, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Martin D, Anklesaria P, Heald AE. A multicenter, double blind, placebo-controlled, Phase IIB study of aerosolized TGAAVCF for the treatment of cystic fibrosis. *Pediatr Pulmonol* 2004; S27: 348.

59. Schechter MS, **Milla C**, Sockrider M, Stark L, Luder E, White L, Powell D, Margolis P. Baseline characteristics do not predict early success by centers participating in a collaborative quality improvement project. *Pediatr Pulmonol* 2004; S27: 348.

60. Billings JL, Mullan B, Sharma S, Connett J, **Milla CE**. The effect of menarche on pulmonary function in women with cystic fibrosis. *Proc Am Thor Soc* 2005, 2: A180.

61. Moss RB, **Milla C**, Colombo J, Accurso F, Zeitlin P, Clancy JP, Spencer T, , Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Martin D, Anklesaria P, Heald AE. A multicenter, double blind, placebo-controlled, Phase IIB study of aerosolized TgAAV-CF as gene therapy for cystic fibrosis. *Proc Am Thor Soc* 2005, 2: A179.

62. Billings JL, **Milla CE**. Clinical characteristics associated with the presence of a CF pulmonary exacerbation. *Pediatr Pulmonol* 2005; S28: 311.

63. Sabati AA; Kempainen RR, **Milla CE,** Blumenthal MN, Schwarzenberg SJ, Dunitz JM, Khan KM. Gastroesophageal Reflux in cystic fibrosis. *Pediatr Pulmonol* 2005; S28: 342.

64. Billings JL, Carlquist D, **Milla CE**. Myostatin influences muscle mass and rate of pulmonary function decline among patients with Cystic Fibrosis (CF). 2006 Pediatric Academic Societies Meeting, *E-PAS*2006:59:4831.100.

65. Harrison AN, Regelmann WE, **Milla CE**. Longitudinal analysis of pulmonary function in Cystic Fibrosis Infants. *Pediatr Pulmonol* 2006; S29:336.

66. Billings JL, Williams C, Sharma S, Connett J, **Milla CE**. Changes in pulmonary function through the menstrual cycle in women with CF. *Pediatr Pulmonol* 2006; S29:394.

67. Kempainen R, Hazelwood A, Williams C, Dunitz J, Billings JL, **Milla CE**. Comparison of airway clearance efficacy of sine and triangular wave High Frequency Chest Wall Oscillation (HFCWO) in patients with cystic fibrosis. *Pediatr Pulmonol* 2006; S29:351.

68. Powers A, Ahrens M, Zirbes J, Reigstad K, **Milla CE**. Early Minnesota Cystic Fibrosis Newborn Screening outcomes at the University of Minnesota and the incorporation of genetic counseling. *Pediatr Pulmonol* 2006; S29:273.

69. Christensen J, Reigstad K, Zirbes J, **Milla CE,** Harris J, Cossette S, Tharp D, Shelstad B, Mertz L. Parents and patients impacting CF Care. *Pediatr Pulmonol* 2006; S29:365.

70. Zirbes J, **Milla CE**. Experience with the use of Omalizumab (Xolair®) in the managment of severe Allergic Bronchopulmonary Aspergillosis in 3 children with CF. *Pediatr Pulmonol* 2006; S29:339.

71. Deterding R, **Milla C**, Barnes M, Engels J, Koenig J, Williams C, Gorden J, Mathews D, Smiley L. Safety and Tolerability of Denufosol Inhalation Solution: Results of a 28-Day Phase 2 Study in 5-7 Year Old Patients with CF. *Pediatr Pulmonol* 2006; S29:306.

72. Sshwartz B, Moran A, Dunitz J, Billings J, Kempainen R, **Milla C**, Schwarzenberg SJ. Body mass index (BMI) and clinical outcomes in Cystic Fibrosis. *Pediatr Pulmonol* 2006; S29:388.

73. Powers A, Ahrens M, Zirbes J, Reigstad K, **Milla CE**. Minnesota Cystic Fibrosis Newborn Screening and the incorporation of genetic counseling. 2006 National Society of Genetic Counselors meeting, Nashville, TN.

74. Pylkas A, **Milla CE**, Dunitz J, Rasmusssen L, Rimmel F, Kempainen R. Effect of functional endoscopic sinus surgery on the respiratory status of adults with cystic fibrosis. *Pediatr Pulmonol* 2007; S30:348.

75. Kuo CS, Zirbes JM, Conrad CK, Cornfield DN, **Milla CE**. Improved nutrition correlates with a decrease in air-trapping in infants with cystic fibrosis. (2008 PAS meeting, Hawaii).

76. Billings JL, Noren B, Williams CB, **Milla** CE. Safety and tolerability of inhaled sodium pyruvate as an antioxidant for patients with cystic fibrosis (CF). *Am J Respir Crit Care Med* 2008; 177: A455.

77. Milla C, Chmiel J, McCoy K, Accurso F, Billings J, Boyle M, Atkinson J, Liou T, Clancy JP, Pilewski J, Acton J, Pearce T. A phase I/II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB-001 in cystic fibrosis patients infected with *Pseudomonas aeruginosa*. *Pediatr Pulmonol* 2008; S31:392.

78. Milla C, Accurso F, Chmiel J, McCoy K, Billings J, Atkinson J, Clancy J, Liou T, Acton J, Lynch S, Burns J, Mayer-Hamblett N, Harris K, Patel R, Tremblay T, Parli T. A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with *P. aeruginosa. Am J Respir Crit Care Med* 2009; 179: A1190.

79. Leigh MW, Davis SD, Zariwala M, Carson JL, Hazucha M, Ferkol T, Atkinson J, Sagel S, Rosenfeld M, Dell S, Olivier K, **Milla C**, Knowles MR. Overview of the Genetic Disorders of Mucociliary Clearance Consortium. Advancing Rare Diseases Research Through Networks and Collaboration Conference, ORDR, NIH, Bethesda, MD July 16 2009.

80. Milla C, Zirbes JM, Matel JL, Cornfield DN. Phenotypic characterization of infants with a genetic based diagnosis of CF. *Pediatr Pulmonol* 2009; S32:380.

81. Zirbes JM, **Milla C.** Lung clearance index in infants with cystic fibrosis with the use of a novel ultrasonic device. *Pediatr Pulmonol* 2009; S32:294.

82. Milla C, Chmiel JF, Accurso FJ, McCoy KS, Billings JL, Atkinson JJ, Clancy JP, Liou TG, Acton JD, Lynch SV, Slusher N, Burns JL, Hamblett-Mayer N, Harris JK, Patel R, Tremblay TM, Parli TJ. Anti-inflammatory effect of KB-001, an anti-PcrV antibody fragment, in CF patients chronically infected with *Pseudomonas aeruginosa*. *Pediatr Pulmonol* 2009; S32:341.

83. Zirbes J, Koepke R, Kharrazi M, **Milla C**, California CF Newborn Screening Consortium. Sweat Chloride (SC) testing performance and concentration by mutation class among infants identified by Cystic Fibrosis (CF) Newborn Screening (NBS) in California. *Pediatr Pulmonol* 2009; S32:381.

84. Milla CE, Accurso FJ, Chmiel J, McCoy K, Billings J, Atkinson J, Clancy JP, Liou T, Acton J, Lynch SV, Slusher NA, Burns J, Mayer-Hamblett N, Harris JK, Patel R, Tremblay T, Parli T. Modulating *Pseudomonas aeruginosa* chronic inflammation with the anti-PcrV antibody KB001: Results of a pilot Clinical and Pharmacodynamic study in subjects with Cystic Fibrosis. *Am J Respir Crit Care Med* 2010; 181:A1845.

85. Zirbes JM, **Milla CE.** Lung clearance Index (LCI) and Moment Analysis Ratios (MAR) in infants with Cystic Fibrosis. *Am J Respir Crit Care Med* 2010; 181:A1831.

86. Buu M, **Milla CE**, Mark J, Cornfield D. A case of surfactant dysfunction from ABCA3 mutation masquerading as asthma. *Am J Respir Crit Care Med* 2010; 181:A3752.

87. Robinson TE, Raman P, **Milla C**, Waltz DA, Goris ML. Lung Density and Quantitative Air Trapping in Infants/Toddlers with Cystic Fibrosis Utilizing Controlled Ventilation Infant CT (CViCT) Scanning. *Am J Respir Crit Care Med* 2010; 181:A1831.

88. Shapiro AJ, Davis SD, Olivier KN, Ferkol TW, Dell SD, Sagel SD, Rosenfeld M, **Milla CE**, Atkinson JJ, Knowles MR, Leigh MW. Clinical Symptoms associated with Primary Ciliary Dyskinesia – Results of a Multi-Centered Study. *Am J Respir Crit Care Med* 2010; 181:A6728.

89. Bedigian A, Dunn C, Davies Z, **Milla CE**, Conrad CK. Diagnosis of pulmonary exacerbations in patients with Cystic Fibrosis. Correlation of patient reported symptoms with physician diagnosis. *Am J Respir Crit Care Med* 2010; 181:A1822.

90. Luna N, Chan J, **Milla C**, Cornfield D, Wise P. Variation in Accredited Specialty Care Hospital Utilization by Cystic Fibrosis Patients in California: A Population Based Study. 2010 PAS Conference, E-PAS20104401.71.

91. Buu M, Luna N, Chan J, Cornfield D, **Milla C,** Wise P. Hospital utilization by Hispanic Cystic Firbosis patients in California. 2010 PAS Conference, E-PAS 20101685.5.

92. Zirbes J, Koepke R, Kharrazi M, **Milla CE**. Sweat Chloride (SC) concentration and CFTR mutation class among infants identified by Newborn Screening (NBS) in California (CA). *J Cystic Fibr* 2010; 9 (Suppl. 1):S7.

93. Zirbes JM, **Milla CE** Lung Clearance Index (LCI) and Nutritional parameters in infants with cystic fibrosis. European Respiratroy Society Annual Congress 2010, Barcelona, Spain.

94. Tirouvanziam R, Zirbes J, **Milla C**. Evidence for airway neutrophil dysfunction in CF newborns and infants. *Pediatric Pulmonology* 2010; S33.

95. Buu M, Luna N, Chan J, Cornfield D, **Milla C**, Wise P. Hospitalizations and death rates of Hispanic cystic fibrosis patients in California. *Pediatric Pulmonology* 2010; S33:390=91.

96. Zirbes JM, **Milla CE**. Lung Clearance Index Detects Early Lung Disease In Asymptomatic Infants With Cystic Fibrosis. *Am J Respir Crit Care Med* 2011; 183: A5723.

97. Pittman JE, Rosenfeld M, LaFave C, Ferkol T, Sagel S, Dell S, **Milla CE**, Johnson RC, Jones P, Leigh MW, Knowles MR, Davis SD. Characteristics of Primary Ciliary Dyskinesia in Children under 5 years of age. 2011 *Am J Respir Crit Care Med* 2011; 183: A1213.

98. Daniels MLA, Baker B, Minnix S, Dell S, Ferkol T, **Milla CE**, Olivier KN, Rosenfeld M, Sagel SD, Carson JL, Davis SD, Leigh M, Knowles MR. The Diagnostic Dilemma of Primary Ciliary Dyskinesia: Finding and Experience of the Genetic Disorders of Mucociliary Clearance Consortium. *Am J Respir Crit Care Med* 2011; 183: A1217.

99. Coates AC, Mark J, Cornfield D, **Milla** CE. Dyspnea in a Patient with Raynaud's Phenomenon: The Uncovering of Interstitial Lung Disease (ILD). *Am J Respir Crit Care Med 2011*; 183: A6475.

100. Tirouvanziam R, Laval j, Gudiputi L, Touhami J, Battini JL, Conrad C, **Milla C**, Moss R, Sitbon M, Herzenberg L. Metabolic conditioning and reprogramming

are hallmarks of neutrophilic inflammation in cystic fibrosis. *Inflammation Research* 2011; 60:S1.

101. Zirbes JM, **Milla CE**. Pulmonary Function Preservation as a Result of Targeted Antibiotic Use in Infants with Cystic Fibrosis. *Eur RespirJ* 2011; 38: Suppl. 55:A4287.

102. Gudiputi L, Aronov P, Makam M, Zirbes J, Conrad C, **Milla C**, Herzenberg L, Moss R, Tirouvanziam R. Metabolite profiling of CF airway fluid suggests a role for catecholamines in early and chronic disease. *Pediatric Pulmonology* 2011; S34:240.

103. Zirbes JM, Hardy K, Kharrazi M, **Milla CE**. Longitudinal assessment of sweat chloride values in infants with 2 CFTR mutations identified by newborn screening. *Pediatric Pulmonology* 2011; S34:370.

104. Prais D, Zirbes JM, Dunn CE, Everson C, **Milla CE**. Assessment of pulmonary function by Nitrogen Washout and Spirometry in preschool age children. *Am J Respir Crit Care Med* 185; 2012:A2346.

105. Hilgendorff A, Parai K, Ertsey R, Navarro E, Jain N, **Milla C**, Mokres L, Carandang F, Starcher B, Rabinovitch M, Bland R. Defective formation of alveoli, micro-vessels and elastic fibers in lungs of mechanically ventilated elastin-haploinsufficient ($Eln^{+/-}$) neonatal mice. *Am J Respir Crit Care Med* 185; 2012:A1221.

106. Zamanian R, Del Rosario P, Hsi A, **Milla C**, Bland R, Nicolls M, Rabinovitch M. Severe Pulmonary Arterial Hypertension is Characterized by Elafin Deficiency despite Excessive Neutrophil Elastase Levels. *Am J Respir Crit Care Med* 185; 2012:A1251.

107. Leigh MW, Shapiro AJ, Pittman JE, Davis SD, Lee H, Krischer J, Ferkol TW, Atkinson JJ, Sagel SD, Rosenfeld M, Dell SD, **Milla C**, Olivier KN, Knowles MR, & Genetic Diseases of Mucociliary Clearance Consortium. Definition of clinical criteria for diagnosis of Primary Ciliary Dyskinesia. *Am J Respir Crit Care Med* 185; 2012:A2483.

108. Leigh MW, Chawla KK, Baker BR, Hazucha MJ, Brown DE, LaVange LM, Horton BJ, Qaqish BF, Carson JL, Davis SD, Dell SD, Ferkol TW, Atkinson JJ, Olivier KN, Sagel SD, Rosenfeld M, **Milla C**, Zariwala MA, Knowles MR, & Genetic Diseases of Mucociliary Clearance Consortium. Standardization of Nasal Nitric Oxide as screening test for Primary Ciliary Dykinesia. *Am J Respir Crit Care Med* 2012; 185:A3898.

109. Zirbes J, Prais D, Dunn C, **Milla C.** Assessment of lung function in pre-school children with cystic fibrosis by nitrogen washout. *Eur Respir J* 2012; 40: Suppl. 56: A1844.

110. Wine J, Kennedy MH, Frisbee E, Cho H, Dunn CE, **Milla, C.** Detection of CFTR-Dependent secretion in individually identifiable sweat glands of a patient homozygous for Δ-F508 CFTR. *Pediatric Pulmonology* 2012; S35:299.

111. Buu M, **Milla C,** Sundarm V, Goldstein B, Wise PH. Patterns of health care utilization in children with cystic fibrosis enrolled in a State program for children with special health care needs. *Pediatric Pulmonology* 2012; S35:381.

112. Coates AC, Helmers M, Matel J, Shelton K, Martins L, Huerta M, Souza C, Cornfield D, **Milla C**. Improving patient and family education and quality of life through an individualized CF action plan and organizational tool. *Pediatric Pulmonology* 2012; S35:390.

113. Smith CC, Prevots DR, Adjemian J, Seitz A, Claypool R, Holland SM, Hall D, **Milla CE** , Czaja CA, Knowles MR, Olivier KN. Characterization of Idiopathic Bronchiectasis in Patients with and without Pulmonary Nontuberculous Mycobacterial Disease. 2013 *Am J Respir Crit Care Med* 2013; 187:A4535.

114. Krasinska KM; **Milla CE**, Chien AS. Practical comparison of LC-MS/MS-based workflows for quantitation of desmosine and isodesmosine in urine. ASMS Conference 2013.

115. Zirbes J, Hardy K, Sudhakar R, Salinas D, Saeed M, Kharrazi M, **Milla C**. Longitudinal values of sweat chloride concentration among infants identified by cystic fibrosis (CF) Newborn Screening (NBS) in California. *J Cystic Fibr* 2013; 12 (S1):S58.

116. Dunn CE, Davies ZA, Everson C, Zirbes J, Kim LJ, **Milla CE**. Comparison of acute effects of conventional high frequency chest oscillation (HFCWO) and hand held percussor (Electro-Flo 5000) for airway clearance in cystic fibrosis patients. *J Cystic Fibr* 2013; 12 (S1):S103.

117. Malkovskiy A, Zirbes JM, Rajadas J, **Milla C**. Physicochemical properties of mucus gel in CF and healthy controls assessed by Raman spectroscopy and force-distance Atomic Force Microscopy. *Eur Respir J* 2013; 42: Suppl.: P2110.

118. Wine JJ, Char J, Kennedy MH, Cho H, Dunn C, Davies Z, **Milla CE**, Park IH, Thomas EAC. Ivacaftor increases CFTR-dependent sweat secretion in G551D CF subjects: Repeated measures from single, identified glands. *Pediatric Pulmonology* 2013; S36:279.

119. Gonska T, Shamsuddin AK, Wine JJ, **Milla CE**, Accurso F, Dupuis A, Avolio J, Hamblett N, Heltshe S, Joseloff E, Durie P, Quinton P, Rowe SM. Effect of Ivacaftor on beta-adrenergic sweat secretion by evaporimetry in patients with the G551D CFTR mutation. *Pediatric Pulmonology* 2013; S36:280.

120. Dunn C, Davies Z, **Milla CE**. Applying Equip-CR to enhance the culture of research: The Stanford Translational CF Research Center experience. *Pediatric Pulmonology* 2013; S36:385-6.

121. Dunn C, Davies Z, Everson C, Zirbes J, Kim L, **Milla CE**. Study of acute effects on pulmonary function and sputum production with high frequency chest oscillation (HFCWO) and Postural Drainage aided by hand held percussion (PD-HP). *Pediatric Pulmonology* 2013; S36:359.

122. Johnson C, Chitkara R, McCarthy E, Fineman JR, Sun C, Kim L, Hintz SR, Van Meurs Krisa P, Punn R, **Milla CE**, and Feinstein JA. Longitudinal plasma Endothelin-1 levels in premature infants with and without bronchopulmonary dysplasia. 2014 WSPR meeting.

123. Yacob A, Zirbes J, Dunn CE, Zamanian R, Bland R, MD1, Rabinovitch M, Nicolls M, **Milla C**. A relative plasma Elafin deficiency in children with cystic fibrosis (CF) is associated with pulmonary disease. Eur Respir J 2014; 44: Suppl.: P1200. (*Accepted as a Late Breaking Abstract).*

124. Abrahamsen K, Petersen K, Nielsen KG, **Milla CE**. Clinical outcomes of children with cystic fibrosis treated with intravenous Tobramycin based o a pharmacokinetic assessment. *Pediatric Pulmonology* 2014; S38:222.

125. Zirbes JM; Hardy K, Sudhakar R, Salinas D, Saeed M, Kharrazi M, **Milla C**. Longitudinal assessment of sweat chloride concentration among infants positive to Newborn Screening (CF NBS) in California. *Pediatric Pulmonology* 2014; S38:473.

126. Char JE, Dunn CE, Davies Z, **Milla CE**, Wine JJ, Moss RB. Estimating Ivacaftor Effects on R117H CFTR Open Probability: Human in Vivo Measurements. *Pediatric Pulmonology* 2014; S38:214.

127. Dunn CE, Davies Z, Yacob A, Everson C, **Milla CE**. A comparison of the acute efficts of two hand held percussive devices, the Electro Flo 5000 and the G5 Flimm-Fighter, for airway clearance in patients with cystic fibrosis (CF). *Pediatric Pulmonology* 2014; S38:429.

128. Yuan N, Zirbes J, Seligman A, **Milla CE**. Multiple breath washout (MBW) in Spinal Muscular Atrophy: A feasibility study. 2015 American Thoracic Society Conference, Denver, CO.

129. Chang H, Adjemian J, Dell SDM, Ferkol TW, Leigh MW, **Milla CE**, Rosenfeld M, Sagel SD, Knowles MR, Olivier KN. Prevalence of Airway Microbial Flora in Primary Ciliary Dyskinesia. 2015 American Thoracic Society Conference, Denver, CO.

130. Rychkova A, Buu MC, Scharfe C, Lefterova M, Odegaard J, **Milla CE**, Schrijver I, Bustamante CD. Improving computational prediction of missense variants pathogenicity for clinically relevant genes. Biology of Genomes 2015 Conefrence, Cold Spring Harbor Laboratory, NY.

131. Abraham WM, Sabater JR, Cohen I, **Milla C**. Brevenal modulates slowed airways mucociliary clearance inhibition induced by the CFTR Inhibitor 172 alone and with Human Neutrophil Elastase. *Pediatric Pulmonology* 2015; S41:289.

132. Davies Z, Yacob A, Dunn CE, Zirbes JM, Ryan S, Fong K, **Milla CE**. Development of an enhanced Beta-adrenergic Sweat Secretion Rate assay as a Cystic Fibrosis Biomarker. *Pediatric Pulmonology* 2015; S41:285.

133. Goss CH, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ, Gibson RL, Orenstein D, **Milla C**, Lechtzin N .Assessment of the effectiveness of home monitoring trial in CF to identify and treat acute pulmonary exacerbation, the eICE Study results. *Pediatric Pulmonology* 2015; S41:402.

134. Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ, Gibson RL, Orenstein D, **Milla C**, Goss CH.The effect of home spirometry and symptom monitoring on treatment adherence in CF. *Pediatric Pulmonology* 2015; S41:628.

135. Sockell AA, Rychkova A, Costa H, **Milla C**, Verkman AS, Bassik MC, Bustamante CD. Defining CFTR Variant Pathogenicity through Computational and Functional Assays. Abstract # 1349. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7, 2015, Baltimore, MD.

136. Robinson TE, Goris ML, **Milla CE**, Kongstad T, Green K, Nielsen KG. Comparison of Lung Clearance Index and Quantitative CT Air Trapping in Infant/Toddler/Preschool Children vs. School Age Children with Cystic Fibrosis (CF). 2016 American Thoracic Society Conference, San Francisco, CA.

137. Tracy MC, Zirbes JM, Hernandez C, Cornfield DN, **Milla CE**. Respiratory Microbiology in Primary Ciliary Dyskinesia: Comparisons to a Pediatric Cystic Fibrosis Cohort. 2016 American Thoracic Society Conference, San Francisco, CA.

138. Sullivan KM, Daniels MLA, Ferkol TW, Atkinson JJ, Lee HS, Rosenfeld M, Sagel SD, **Milla C**, Olivier KN, Hall D, Metjian HM, Zariwala MA, Carson JL, Krischer J, Hazucha MJ, Knowles MR, Leigh MW. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Adults. 2016 American Thoracic Society Conference, San Francisco, CA.

139. Kao J, Zirbes JM, Conrad CK, **Milla CE**. Monitoring Allograft Function in Post Lung Transplant Children by Multiple Breath Washout Demonstrates Peripheral Lung Ventilation Inhomogeneity. 2016 American Thoracic Society Conference, San Francisco, CA.

140. **Milla CE**, Zirbes JM, Yacob A, Tian L, Zamanian RT, Bental-Roof M, Bland R, Rabinovitch M, Dhillon G, Nicolls M. Elastase Confers a High Risk for the Development of Bronchiolitis Obliterans Syndrome. 2016 American Thoracic Society Conference, San Francisco, CA.

141. Burgener E, **Milla CE**. Eosinophilic Pneumonitis as Initial Presentation of Acute Lymphoblastic Leukemia. 2016 American Thoracic Society Conference, San Francisco, CA.

142. Tracy MC, Yacob A, Chen C, **Milla CE**, Cornfield DN. DNA extraction From Cystic Fibrosis Sputum Samples is not Method Dependent. 2016 American Thoracic Society Conference, San Francisco, CA.

143. Zirbes JM, **Milla CE**. Longitudinal assessment of sweat chloride values among infants identified by newborn screening. *J Cystic Fibr* 2016; 15 (S1):S62.

144. Zirbes JM, **Milla CE**. Clinical benefit of ivacaftor on patient with 3849+10 Kb C>T CFTR mutation. *J Cystic Fibr* 2016; 15 (S1):S18.

145. **Milla CE**, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenflked M. Results from an open label Phase 3 study evaluating the safety, tolerability, and pharmacodynamics of combination lumacaftor/ivacaftor (LUM/IVA) therapy in children aged 6 through 11 years with cystic fibrosis (CF) homozygous for the F508del CFTR mutation. *J Cystic Fibr* 2016; 15 (S1):S.

146. Zirbes J, Yacob A, **Milla C**. Inflammatory profiling of infants with CF and CRMS identified through newborn screening. *Pediatric Pulmonology* 2016; S45:390.

147. **Milla C**, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M. Safety, tolerability, and pharmacodynamics of combination Lumacaftor/Ivacaftor therapy in patients aged 6-11 years with CF homozygous for the F508del CFTR mutation. *Pediatric Pulmonology* 2016; S45:259.

148. Abraham W, Sabater J, McClain D, Ball R, Cohen I, **Milla C.** Brevenal is comparable to aerosol Ivacaftor in reversing the slowed mucus transport induced by airway challenge with CFTR-INH172 alone or in combination with Human Neutrophil elastase in sheep. *Pediatric Pulmonology* 2016; S45:222.

149. Mouded M, Layish D, Sawicki GS, **Milla C**, Flume PA, Tolle J, Vansaghi L, Watson C, Munoz B, Bhalla A, Ivarsson M, Lee P. Phase I intial results evaluating safety, tolerability, PK and biomarker data using PTI-128, a novel CFTR modulator, in patients with cystic fibrosis. *Pediatric Pulmonology* 2016; S45:262.

150. Falk-Libby E, Fortinberry H, Birket S, **Milla C,** Cohen I, Tearney GJ, Rowe SM. Brevenal increases airway surface liquid in F508del HBE cells. *Pediatric Pulmonology* 2016; S45:292.

151. Sellers Z, Barth R, **Milla C.** Re-thinking CF liver disease screening to identify early disease. *Pediatric Pulmonology* 2016; S45:433.

152. Falk-Libby E, Fortinberry H, Birket SE, **Milla C**, Baen D, Bourdelais A, Salathe M, Cohen I, Abraham WM, Tearney G, Rowe SM. Brevenal Effect Alone and with Orkambi on Airway Suface Liquid and Mucociliary Transport in Cystic Fibrosis Primary Human Bronchial Epithelial Cells. 2017 American Thoracic Society Conference.

153. Abraham WM, Sabater JR, McClain D, Ball RW, Baden DG, Bourdelais A, Salathe M, Cohen I, **Milla C**. Doses of aerosol Brevenal but not Ivacaftor that correct slowed mucus transport caused by CFTRinh-172 + Human Neutophil Elastase (HNE) challenge block HNE-induced bronchoconstriction in sheep. 2017 American Thoracic Society Conference.

154. Shapiro AJ, Davis SD, Dell SD, Ferkol TW, Rosenfeld M, Sagel S, **Milla C**, Olivier KN, Zariwala MA, Knowles M, M. Leigh M. Children with Primary Ciliary Dyskinesia and Situs Ambiguus Have Worse Clinical Outcomes. 2017 American Thoracic Society Conference.

155. Falk Libby E, Fortinberry H, Birket SE, **Milla C**, Baden D, Bourdelais A, Salathe M, Cohen I, Abraham WM, Tearney GJ, Rowe SM. Effect of Brevenal as a single agent and combined with Orkambi on airway surface liquid and mucociliary transport in CF primary human bronchial epithelial cells. 14th ECFS Basic Science Conference, Albufeira, Portugal.

156. Abraham WM, Sabater J, McClain D, Ball RW, Beerman M, Baden DG, Bourdelais A, Salathe M, **Milla C**, Cohen I. The anti-inflammatory activity of the

mucociliary clearance agent brevenal enhances the efficacy of cystic fibrosis therapies. *J Cystic Fibr 2017*; 16 (S1):S38.

157. Ratjen F, Tian S, Marigowda G, Hug C, Huang X, Stanojevic S, **Milla CE**, Robinson P, Waltz D, Davies JC .Efficacy and safety of lumacaftor/ivacaftor (LUM/IVA) in patients (pts) aged 6 through 11 years (yrs) with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation: a randomized placebo (PBO)-controlled phase 3 trial. *J Cystic Fibr* 2017; 16 (S1):S24.

158. Burgener E, Yacob A, Bollyky P, **Milla CE**. Pf bacteriophage (Pf) in Pseudomonas aeruginosa (Pa) biofilms is associated with increased elastase in the sputum of patients with cystic fibrosis (CF). *J Cystic Fibr 2017*; 16 (S1):S90.

159. Stevens E, Vladar EK, Alanin MK, Marshall W, Marthin JK, Nielsen KG, Von Buchwald C, **Milla C**. Assessment of a ciliary transport protein in airway cells reveals novel pattern in cystic fibrosis. ERS Congress, Late Breaking Abstract 5382, Milan, Sept. 10 2017.

160. Stevens, E.; Vladar, E.; Leitman, D.; Yuan, C.; Baden, D.; Bourdelais, A.; Abraham, W.M.; Salathe, M.; Cohen, I.; **Milla, C.** The voltage-sensitive Sodium channel NaV1.7 is expressed in human airway epithelial cells providing support for the mechanism of action of the mucocilaiy agent Brevenal. *Pediatric Pulmonology* 2017; 52 (S47): 326.

161. Abraham, W.M.; Sabater, J.; McClain, D.; Ball, R.; Beerman, M.; Baden, D.; Bourdelais, A.; Salathe, M.; **Milla, C.**; Cohen, I. Aerosolized Brevenal and UTP, but not Ivacaftor can reverse slowed tracheal mucus velocity produced by CaCC-INH-AO1 aerosol in sheep. *Pediatric Pulmonology* 2017; 52 (S47): 328.

162. Burgener, E.B.; Sweere, J.M.; Bollyky, P.L.; **Milla, C.** Pf Bacteriophage in patients with cystic fibrosis is associated with increased sputum elastase and Pseudomoans aeruginosa load. *Pediatric Pulmonology* 2017; 52 (S47): 350.

163. Somayaji, R.; Lechtzin, N.; Ramos, K.J.; Hamblett, N.M.; West, N.E.; Allgood, S.J.; Wilhelm, E.; Khan, U.; Aitken, M.L.; Ramsey, B.W.; Boyle, M.P.; Mogayzel, P.; Gibson, R.L.; Orenstein, D.; **Milla, C.**; Clancy, J.P.; Antony, V.; Goss, C.H. Lung function recovery in cystic fibrosis following a pulmonary exacerbation treated with intravenous and oral antibiotics: Analysis of the eICE trial. *Pediatric Pulmonology* 2017; 52 (S47): 383.

164. Zirbes, J.M.; **Milla C.** Fungal colonization in early life in a CF cohort identified by newborn screening. *Pediatric Pulmonology* 2017; 52 (S47): 411.

165. Sellers, Z.; Isaacson, J.; Barth, R.; **Milla, C**. Correlation of Ultrasound elastrography and Magnetic Resonance elastography to detect liver fibrosis in cystic fibrosis. *Pediatric Pulmonology* 2017; 52 (S47): 447.

166. Sellers, Z.; Barth, R.; **Milla, C.** Routine use of abdominal ultrasound improves detection of liver disease in cystic fibrosis: A pediatric CF Center's experience. *Pediatric Pulmonology* 2017; 52 (S47): 448.

167. Strassle, C.; Naranjo, D.; Moreno, R.M.; Dunn, C.; Carro, L.M.; **Milla, C.** Social support and its implications for health in patients with cystic fibrosis: Results of an international study across two cultures. *Pediatric Pulmonology* 2017; 52 (S47): 483.

168. Naranjo, D.; Barley, R.C.; Veeravalli, S.; Hernandez, C.; Adams, R.; **Milla, C.** Mental health screening feasibility and outcomes in a large pediatric CF center. *Pediatric Pulmonology* 2017; 52 (S47): 499.

169. Davis S. D., Rosenfeld M., Lee H., Ferkol T. W., Sagel S. D., Dell S. D., **Milla C. E.**, Zariwala M. A., Knowles M. R., Leigh M. W. Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease Progression by Ultrastructural Defect and Genotype. American Thoracic Society 2018 Conference.

170. Burgener E., **Milla C.** Diffuse Large Pulmonary Nodules in a Young Child: Is it Always Metastatic? American Thoracic Society 2018 Conference.

171. Withers A. L., Wilson A. C., Buu M., **Milla C. E.**, Zirbes J. M., Hall G. L. The Natural History of Declining Pulmonary Function in Children with Duchenne Muscular Dystrophy. American Thoracic Society 2018 Conference.

172. Burgener E, Sweere J, Secor P, Bollyky P, **Milla C**. Pf bacteriophage in patients with cystic fibrosis is associated with chronic Pseudomonas infection. *Pediatr Pulmonol* 2018; 53(S2):281.

173. Salathe M, Chung S, Baumlin N, Baden D, Bourdelais A, Sabater J, Abraham WM, **Milla C**, Cohen I. Brevenal increases ciliary beat frequency and particle diffusion in airway surface liquid of cystic fibrosis human bronchial epithelial cells with nonsense mutations. *Pediatr Pulmonol* 2018; 53(S2):253.

174. Zirbes JM, Alvarez D, Ryan SP, **Milla C**. Defining the clinical utility of the lung clearance index. *Pediatr Pulmonol* 2018; 53(S2):248.

175. Vladar EK, **Milla C**, Axelrod J. Abnormal basal cells underlie epithelial dysfunction in cystic fibrosis. *Pediatr Pulmonol* 2018; 53(S2):175.

176. Chilvers M, Davies JC, Ratjen F, **Milla C**, Owen CA, Tian S, Han Z, Wang LT. Long-term safety and efficacy of lumacaftor/ivacaftor (LUM/IVA) therapy in patients (pts) aged 6-11 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation (F/F). *J Cystic Fibr* 2019; 17 (S1), Selected for platform presentation, 2019 European Cystic Fibrosis Conference.

177. Zirbes J, Alvarez D, Ryan S, **Milla C**. Lack of correlation between patient reported outcomes (PROs) and Lung Clearance Index ($LCI_{2.5}$) among cystic fibrosis children with normal spirometry. *J Cystic Fibr* 2019; 17 (S1), Selected for platform presentation, 2019 European Cystic Fibrosis Conference.

178. Burgener E, Sweere J, Bach MS, Secor PR, Bollyky PL, Milla C. Pf bacteriophage burden in airway is associated with FEV1 change in patients with cystic fibrosis and Pseudomonas infection. *Pediatr Pulmonol* 2019; 54(S2):306.

PRESENTATIONS

1. "Comparison of the decline in pulmonary function in deceased cystic fibrosis patients homozygous for the ΔF508 mutation versus compound heterozygotes for the ΔF508 mutation". Presented at the mini-symposium 'Cystic fibrosis: clinical studies', 1993 American Thoracic Society international conference, San Francisco, California, May 1993.

2. "Case presentation: Interaction of AIDS with cystic fibrosis in a 41 year old patient homozygous for ΔF508". Presented at the 'Fellows' clinical session', 7th North American Cystic Fibrosis Conference, Dallas, Texas, October 1993. (One of the seven presentations selected from a worldwide contest sponsored by the Cystic Fibrosis Foundation)

3. "A preventive medicine approach to asthma". Presented at the 4th Latin-American Pediatric Pulmonology Congress, Porlamar, Venezuela, September 1994.

4. "Cystic fibrosis: diagnostic tools and therapeutic management". Presented at the 4th Latin-American Pediatric Pulmonology Congress, Porlamar, Venezuela, September 1994.

5. "Development of a new method to study intraphagocytic bacterial killing". Presented at the Infectious Disease Session, 1995 Society for Pediatric Research meeting, San Diego, California, May 1995.

6. "Potential usefulness of cyclosporine as an antiinflammatory drug in cystic fibrosis patients with advanced lung disease". Presented at the discussion session 'Airway Inflammation in Cystic Fibrosis', 1995 American Thoracic Society international conference, Seattle, Washington, May 1995.

7. “Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis patients with severe pulmonary function impairment”. Presented at the workshop ‘Latest Nutrition Research’, 9th North American Cystic Fibrosis Conference, Dallas, Texas, October 1995.

8. “Nutrition in the acutely ill cystic fibrosis patient with CO_2 retention”. Presented at the workshop ‘Gastrointestinal and metabolic complications in cystic fibrosis’, 9th North American Cystic Fibrosis Conference, Dallas, Texas, October 1995.

9. “Longitudinal studies in cystic fibrosis”. Department of Pediatrics Grand Rounds, University of Minnesota, November 8 1995.

10. "Update on Cystic Fibrosis Clinical Research". Department of Pediatrics Grand Rounds, University of Minnesota, August 26 1998.

11. "Cystic Fibrosis for the Primary Practitioner". Department of Pediatrics Grand Rounds, St. Paul Regions Hospital, November 20 1998.

12. “Respiratory Control Disorders in Children”. Topics and Advances in Pediatrics Course, University of Minnesota, June 18 1999.

13. “New Developments in Cystic Fibrosis”. Department of Pediatrics Grand Rounds, University of Minnesota, October 27 1999.

14. “RSV Infection: What is new with an old problem?” Department of Pediatrics Grand Rounds, St. Paul Regions Hospital, February 11, 2000.

15. “RSV Bronchiolitis: current recommendations for treatment and prevention”. Grand Rounds, Fariview Lakes Regional Area Hospital, November 3, 2000.

16. “Management of cystic fibrosis related diabetes: role of the pulmonologist”. 14th North American Cystic Fibrosis Conference, Baltimore, Maryland, November 9, 2000.

17. “Can airway remodeling be modulated?” International Asthma Symposium, Lima, Peru, August 24 2001.

18. “Safety of inhaled corticosteroids use in children”. International Asthma Symposium, Lima, Peru, August 25 2001.

19. “At what age could inhaled corticosteroids be started in children?” International Asthma Symposium, Lima, Peru, August 25 2001.

20. "Insulin and Glucose Excursion Following Pre-Meal Insulin Lispro or Repaglinide in CFRD". 15th North American Cystic Fibrosis Conference, Orlando, FL, October 26 2001.

21. "Current concepts in Acute Bronchioltis". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 18 2002.

22. "Acute Asthma Crisis: Update on evaluation and management in Pediatrics". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 19 2002.

23. "Rationale for combination therapy in Pediatric Asthma". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 19 2002.

24. "State of the Art: Cystic Fibrosis". III Pediatric Pulmonology Congress, Venezuelan Society of Pediatric Pulmonology, Valencia, Venezuela, July 19 2002.

25. "Pulmonary complications in Children with Hurler's syndrome (MPS I)". 6th International COGENT meeting, Lucerne, Switzerland, September 15 2002.

26. "Innovative Care in Cystic Fibrosis: High Performing Centers". Improving Care for Children with CF Expert Meeting, New Orleans, October 2 2002.

27. "Body Mass and Pulmonary Function in Cystic Fibrosis". Research In Progress Conference, Pediatric and Adult Pulmonary Divisions Combined Conference, University of Minnesota Medical School, December 19, 2002.

28. "Clinical Information Systems – Using Data for Clinical Care". NICHQ Improving Care for Children with Cystic Fibrosis, Nashville, TN, February 6, 2003.

29. "Evidenced Based Care: Decision Support and Guidelines for Treatment: Nutrition". NICHQ Improving Care for Children with Cystic Fibrosis, Nashville, TN, February 7, 2003.

30. "Concept Proposal: Pharmacogenomics of Drug Responses in CF". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, WA, April 3, 2003.

31. "Delivery System Design: Building Effective Teams". NICHQ Improving Care for Children with Cystic Fibrosis, San Antonio, TX, April 7, 2003.

32. "Clinical Information Systems: Key components and CFF Patient Registry Implementation". NICHQ Improving Care for Children with Cystic Fibrosis, San Antonio, TX, April 7, 2003.

33. "Cystic Fibrosis Pulmonary Exacerbations" Session Chair. 17th North American Cystic Fibrosis Conference, Annaheim, California, October 17 2003.

34. "What is a Cystic Fibrosis pulmonary exacerbation?" 17th North American Cystic Fibrosis Conference, Annaheim, California, October 17 2003.

35. "Females with CF Related Diabetes are at higher risk for early mortality". 17th North American Cystic Fibrosis Conference, Annaheim, California, October18 2003.

36. "Database development for patient care". NICHQ Improving Care for Children with Cystic Fibrosis, Houston, TX, November 17, 2003.

37. "Implementation of an interdisciplinary management model for malnutrition in children with CF". Cystic Fibrosis QI Leadership Collaborative, Baltimore, MD, January 26 2004.

38. "Data driven Quality Improvement: Experience with the Learning and Leadership Collaborative". 18th North American Cystic Fibrosis Conference, St Louis, Missouri, October13 2004.

39. "Implementation of an interdisciplinary management model for malnutrition in children with CF". 18th North American Cystic Fibrosis Conference, St Louis, Missouri, October15 2004.

40. "Pulmonary exacerbations in Cystic Fibrosis: Introduction" (Workshop Chair). 18th North American Cystic Fibrosis Conference, St Louis, Missouri, October16 2004.

41. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. Eden Prairie, Minnesota, November 2 2004.

42. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. Chapel Hill, North Carolina, December 2 2004.

43. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. St Louis, Missouri, February 4 2005.

44. "Early lung disease: Improving the health of patients with Cystic Fibrosis". Early Intervention Educational Series. Salt Lake City, Utah, February 17 2005.

45. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. Durham, North Carolina, April 21, 2005.

46. "Newborn Screening for Cystic Fibrosis". Advisory meeting for the Newborn Screening Program, Minnesota State Department of Health, St. Paul, MN, April 26, 2005.

47. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. New York, New York, May 9, 2005.

48. "Gene Therapy for Cystic Fibrosis: Why, How and When?" Department of Pediatrics Grand Rounds, University of Minnesota Medical School, June 1, 2005.

49. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. San Diego, California, June 8, 2005.

50. "Inflammation in the Cystic Fibrosis Lung". Cystic Fibrosis Inflammation Educational Series. Houston, Texas, July 14, 2005.

51. "Viral Bronchiolitis". 2005 International Pediatric Specialties Congress, Curitiba, Parana, Brazil, August 27 2005.

52. "Asthma, Rhinitis and the Influence of the Weather". 2005 International Pediatric Specialties Congress, Curitiba, Parana, Brazil, August 27 2005.

53. "Evaluation of the Child with Chronic Cough". 2005 International Pediatric Specialties Congress, Curitiba, Parana, Brazil, August 27 2005.

54. "Aggressive Nutritional Intervention Improves Survival in CF". 19th North American Cystic Fibrosis Conference, Baltimore, Maryland, October 21 2005.

55. "Innovative Approaches to Chronic Care in Pediatrics". Pediatrics Intelligence Conference, Chicago, Illinois, November 4 2005.

56. "Upcoming Statewide Newborn Screening for Cystic Fibrosis". Department of Pediatrics Grand Rounds, University of Minnesota Medical School, December 7, 2005.

57. "Filling the pipeline: Efficient Protocol Development and Lessons Learned". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, Washington, April 27, 2006.

58. "Respiratory Therapies in Cystic Fibrosis". 29th National Pediatric Congress, National Pediatric Confederation of Mexico, Guadalajara, Mexico, May 4 2006.

59. "Chronic Cough". 29th National Pediatric Congress, National Pediatric Confederation of Mexico, Guadalajara, Mexico, May 4 2006.

60. "Novel Approaches to the Assessment and Treatment of CF Lung Disease: Introduction". Session Chair, 2006 American Thoracic Society Meeting, San Diego, California, May 23 2006.

61. "Reviewing a Protocol". Introduction to CF Clinical Research Course, Denver, Colorado, November 1 2006.

62. "CF Pulmonary exacerbations". Roundtable moderator, 20th North American Cystic Fibrosis Conference, Denver, Colorado, November 4 2006.

63. "Overview of the Inflammatory Process in Cystic Fibrosis". 20th North American Cystic Fibrosis Conference, Denver, Colorado, November 4 2006.

64. "Respiratory Issues in Infants with Cystic Fibrosis". Newborn Screening for Cystic Fibrosis Workshop, Genetic Diseases Branch, California Department of Health, Richmond, California, March 22 2007.

65. "KB001 Human Antibody to Treat / Prevent *Pseudomonas* Infections: Clinical development plan". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, Washington, April 19, 2007.

66. "CF Related Diabetes and progression of lung disease". Pulmonary Medicine and Biology Grand Rounds, Stanford University, April 27 2007.

67. "Newborn Screening for Cystic Fibrosis: Introductory remarks". California CF Consortium 2007 meeting, Los Angeles, California, June 23 2007.

68. "Pulmonary Function testing in Cystic Fibrosis: Infants to Adults". 21st North American Cystic Fibrosis Conference, Anaheim, California, October 3 2007.

69. "The inflammatory process in CF: A complex picture with many players. Introductory remarks". 21st North American Cystic Fibrosis Conference, Anaheim, California, October 6 2007.

70. "Improving Children's Health Through Expanded Newborn Screening and Preventative care: Cystic Fibrosis". Session moderator. Palo Alto, California, February 9 2008.

71. "A Phase I/II Study of KB-001 in Cystic Fibrosis Patients Infected with *Pseudomonas aeruginosa*". Cystic Fibrosis Therapeutics Development Network, Spring Meeting, Seattle, Washington, April 2, 2008.

72. “Accelerating the Rate of Improvement in Cystic Fibrosis Cares: Smart Change ideas for Pulmonary Care”. Cystic Fibrosis QI Leadership Collaborative, Hartford, CT, June 3 2008.

73. “Transition to Adult Care Consensus Panel: Pediatric Perspective”. California Cystic Fibrosis Consortium Spring Meeting, San Francisco, CA, June 6 2008.

74. “Progress in Cystic Fibrosis Research: Picking up the pace on the road to the cure”. CFRI Annual Conference, Redwood City, CA, August 2 2008.

75. “CF NBS screen positive G542X/5T-12TG Case report”. California CF NBS meeting, 22nd North American Cystic Fibrosis Conference, Orlando, FL, October 24 2008.

76. “How to make the most effective use of High Frequency Chest Wall Oscillation (HCFWO)”. 22nd North American Cystic Fibrosis Conference, Orlando, FL, October 24 2008.

77. “Controlling infection in the Cystic Fibrosis patient”. Cystic Fibrosis Community Case Exchange series. Chapel Hill, NC, November 6 2008.

78. “Nutrition and lung disease in Cystic Fibrosis”. University of Tennesse, Le Bonheur Children’s Medical Center, Cystic Fibrosis Conference. Memphis, TN, November 16 2008.

79. “Controlling infection in the Cystic Fibrosis patient”. Cystic Fibrosis Community Case Exchange series. San Francisco, CA, November 18 2008.

80. “Lung Defense Mechanisms: Lessons Learned from Cystic Fibrosis”. Department of Pediatrics Grand Rounds, Stanford University Medical School. Palo Alto, CA, December 19 2008.

81. “A Phase I/II Study of the Anti-PcrV Antibody KB001 in Cystic Fibrosis Patients with *P. aeruginosa”*. Poster Discussion Session: New Data Regarding Cystic Fibrosis. 2009 American Thoracic Society Meeting. San Diego, CA, May 17 2009.

82. Pulmonology Platform Session. Session Co-Chair, 2009 Society for Pediatric Research meeting, Baltimore, MD, May 5 2009.

83. “Does IgE blockade have a role in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA)?” ISHAM Working Group on Fungal Respiratory Infections in Cystic Fibrosis. Angers, France, June 7 2009.

84. "An Update on Cystic Fibrosis Epidemiology". Pediatric Grand Rounds, University of Nevada Medical School, Reno, NV, August 13 2009.

85. "Current Concepts on Cystic Fibrosis Pathophysiology". Cystic Fibrosis Update Workshop, Chilean Secretary of Health, Santiago, Chile, August 31 2009.

86. "Early Intervention in Cystic Fibrosis Lung Disease". Cystic Fibrosis Update Workshop, Chilean Secretary of Health, Santiago, Chile, August 31 2009.

87. "Pulmonary Exacerbations and Infection in Cystic Fibrosis". Cystic Fibrosis Update Workshop, Chilean Secretary of Health, Santiago, Chile, September 2 2009.

88. "Pulmonary function in Cystic Fibrosis". Cystic Fibrosis Update Workshop, Chilean Secretary of Health, Santiago, Chile, September 2 2009.

89. "Who wants to be a Cystic Fibrosis Expert?: Understanding New Therapies Targeted at the Underlying CF Disease". Satellite Seminar, 23rd North American Cystic Fibrosis Conference, Minneapolis, MN, October 15 2009.

90. "Cystic Fibrosis Update". Department of Pediatrics Grand Rounds, Loma Linda University Medical School, Loma Linda, CA, November 6 2009.

91. "Early Manifestations of Lung Disease in Cystic Fibrosis". Cystic Fibrosis Annual Conference, Fundacion Sira Carrasco, Madrid, Spain, February 19 2010.

92. "Current state of diagnostic and therapeutic approaches in cystic fibrosis". 69th Congress of the Mexican Pulmonology and Thoracic Surgery Society, Guadalajara, Mexico, April 6th 2010.

93. "How to Guarantee Success in a Cystic Fibrosis Center". 69th Congress of the Mexican Pulmonology and Thoracic Surgery Society, Guadalajara, Mexico, April 7th 2010.

94. "Early features of cystic fibrosis in the lungs". 2010 Argentinian Congress on Cystic Fibrosis, Buenos Aires, Argentina, April 23 2010.

95. "Pulmonary Exacerbactions in Cystic Fibrosis". 2010 Argentinian Congress on Cystic Fibrosis, Buenos Aires, Argentina, April 23 2010.

96. "Emerging Therapies in Cystic Fibrosis". 2010 Argentinian Congress on Cystic Fibrosis, Buenos Aires, Argentina, April 23 2010.

97. Pulmonology Platform Session. Session Co-Chair, 2010 Society for Pediatric Research meeting, Vancouver, BC, May 1 2010.

98. “Consensus on the management of infants identified by CF newborn screening”. California Newborn Screening Program Meeting, California Department of Public Health – Genetic Disease Branch, Richmond, CA, June 25 2010.

99. “Nutrition and Lung Disease in Cystic Fibrosis”. 8th Pediatric Pulmonology Congress and 12th Cystic Fibrosis Conference, Latin American Society of Pediatric Pulmonology (SOLANEP), Cartagena, Colombia, August 20 2010.

100. “Pulmonary Exacerbations in Cystic Fibrosis: Treatment and Prevention”. 8th Pediatric Pulmonology Congress and 12th Cystic Fibrosis Conference, Latin American Society of Pediatric Pulmonology (SOLANEP), Cartagena, Colombia, August 20 2010.

101. “Early Lung Disease in Infants with Cystic Fibrosis”. 8th Pediatric Pulmonology Congress and 12th Cystic Fibrosis Conference, Latin American Society of Pediatric Pulmonology (SOLANEP), Cartagena, Colombia, August 20 2010.

102. “Strategies to Improve Adherence to Treatment in Cystic Fibrosis”. 8th Pediatric Pulmonology Congress and 12th Cystic Fibrosis Conference, Latin American Society of Pediatric Pulmonology (SOLANEP), Cartagena, Colombia, August 20 2010.

103. “The Importance of Good Nutrition in Cystic Fibrosis”. 8th Pediatric Pulmonology Congress and 12th Cystic Fibrosis Conference, Latin American Society of Pediatric Pulmonology (SOLANEP), Satellite Family Conference, Cartagena, Colombia, August 21 2010.

104. “Pathogenesis of Early Lung Disease in Cystic Fibrosis”. 7th Latin American Thoracic Society (ALAT) Conference, Lima, Peru, October 5 2010.

105. “Severe Asthma in Children”. 7th Latin American Thoracic Society (ALAT) Conference, Lima, Peru, October 5 2010.

106. “Update on therapeutic developments in Cystic Fibrosis”. Sor Maria Ludovica Children’s Hospital, La Plata, Argentina, April 7 2011.

107. Clinical and Translational Pulmonology Platform Session. Session Co-Chair, 2011 Society for Pediatric Research meeting, Denver, CO, May 3 2011.

108. “ABPA: Biomarkers for diagnosis and disease staging”. Second Meeting of the ECMM/ISHAM Working Group on Fungal Repiratory Infections in Cystic Fibrosis, Angers, France, September 1 2011.

109. "Ecology of the airway microbiome in Cystic Fibrosis". Second Meeting of the ECMM/ISHAM Working Group on Fungal Repiratory Infections in Cystic Fibrosis, Angers, France, September 2 2011.

110. "Recent Advances in Cystic Fibrosis". Continuing Medical Education series for Cystic Fibrosis, New York, NY, October 25 2011.

111. "Diagnostic Challenges in a Screened Population: the California CF Newborn Screening Program Experience". 25th North American Cystic Fibrosis Conference, Anaheim, California, November 3 2011.

112. "Fungal Infections in Cystic Fibrosis". Roundtable moderator, 25th North American Cystic Fibrosis Conference, Anaheim, California, November 5 2011.

113. "Cystic Fibrosis in the era of Newborn Screening". Pediatric Grand Rounds, Children's Hospital of Central California, Fresno, California, April 19 2012.

114. "Palliative Care for Cystic Fibrosis: Medical Intervention". IV Brazilian Cystic Fibrosis Congress, Florianopolis, SC, Brazil, May 3 2012.

115. "Startegies to Enhance Adherence to Therapy in Cystic Fibrosis". IV Brazilian Cystic Fibrosis Congress, Florianopolis, SC, Brazil, May 4 2012.

116. "Pulmonary Management of Infants with CF Diagnosed by Newborn Screening". IV Brazilian Cystic Fibrosis Congress, Florianopolis, SC, Brazil, May 5 2012.

117. "Recent Advances in Cystic Fibrosis". Continuing Medical Education series for Cystic Fibrosis, Chicago, IL, September 18 2012.

118. "Bronchopulmonary Dysplasia with Pulmonary Hypertension: Current Concepts". 6th Argentinian Pediatric Pulmonology Congress, Buenos Aires, Argentina, November 22 2012.

119. "Advances in the Management of Primary Ciliary Dyskinesia". 6th Argentinian Pediatric Pulmonology Congress, Buenos Aires, Argentina, November 23 2012.

120. "New Developments in the Treatment of Cystic Fibrosis". 6th Argentinian Pediatric Pulmonology Congress, Buenos Aires, Argentina, November 24 2012.

121. "Evidenced-Based Therapies in Cystic Fibrosis: Defining the Goals". Continuing Medical Education series for Cystic Fibrosis, Lubbock, TX, December 12 2012.

122. “Physicochemical properties of mucus gel in CF and healthy controls assessed by Raman spectroscopy and force-distance Atomic Force Microscopy”. Poster Discussion Session: Cystic Fibrosis basic and applied science. 2013 European Respiratory Society Congress. Barcelona, Spain, September 9 2013.

123. “Updates on ACT and inhalation therapies”. Session Co-Chair, 27th North American Cystic Fibrosis Conference, Salt Lake City, UT, October 17 2013.

124. “Lung Clearance Index: Practical considerations”. Roundtable moderator, 27th North American Cystic Fibrosis Conference, Salt Lake City, UT, October 19 2013.

125. “Hot topics in PCD: Primary ciliary dyskinesia and heterotaxia post-heart transplantation”. Primary ciliary dyskinesia: sharing knowledge and experience across Europe, European Respiratory Society. Naples, Italy, November 21 2013.

126. “Building consensus around practices for CF NBS infants”. 2014 California CF Consortium Conference, Carmel, CA, January 25 2014.

127. “Progress in Primary Ciliary Dyskinesia”. Department of Pediatrics Grand Rounds, University of West Virginia, Morgantown, WV March 12 2014.

128. “Novel in-vivo biomarkers of CFTR function: A tale of two glands”. Fifth Annual Department of Pediatrics Research Retreat, Stanford University School of Medicine, April 4 2014.

129. “The microbiome in the Cystic Fibrosis Lung”. Pulmonary Division Conference, Riley Hospital for Children, Indiana University School of Medicine Department of Pediatrics, Indianapolis, IN April 22 2014.

130. “Understanding the Complexities in Cystic Fibrosis Care”. Continuing Medical Education series for Cystic Fibrosis, Children’s Mercy Hospital, Kansas City, MO, May 9 2014.

131. Primary Ciliary Dyskinesia (PCD) on the Move: 1st International Conference. Conference Co-Chair; San Francisco, CA, September 18 – 19 2014.

132. “Practical demonstration of nasal biopsies for ciliated studies”. Primary Ciliary Dyskinesia (PCD) on the Move 1st International Conference, San Francisco, CA, Spetember 18th 2014.

133. “Consensus statement on the management of infants identified by CF NBS in California”. California CF Newborn Screening Interest Group meeting, 28th North American Cystic Fibrosis Conference, Atlanta, GA, October 9 2014.

134. “Recent Advances in Cystic Fibrosis”. 10th Pediatric Pulmonology Congress, Latin American Society of Pediatric Pulmonology (SOLANEP), Rivera Maya, Mexico, November 14 2014.

135. “Understanding the Complexities in Cystic Fibrosis Care”. Continuing Medical Education series for Cystic Fibrosis, Omaha, NE, November 18 2014.

136. “Consensus report on the treatment for the first year of life of infants identified by CF Newborn Screening in California”. 2015 California CF Consortium Conference, Carmel, CA, January 30 2015.

137. “Management of Chronic Respiratory Failure Due to Neuromuscular Disease”. 2015 California Thoracic Society Conference, Carmel, CA, January 31 2015.

138. “Pseudomonas type III secretion inhibition”. 2015 European Cystic Fibrosis Society Conference, Brussels, Belgium, June 13 2015.

139. “Application of Gene Sequencing to CF Newborn Screening”. 2nd Colombian Cystic Fibrosis Congress, Bogota, Colombia, September 4 2015.

140. “Relatioship between Nutrition and Lung Disease in Cystic Fibrosis”.2nd Colombian Cystic Fibrosis Congress, Bogota, Colombia, September 4 2015.

141. “Monitoring of Lung Fucntion in Csytic Fibrosis”. 2nd Colombian Cystic Fibrosis Congress, Bogota, Colombia, September 5 2015.

142. “Management of Uncertain Cases in Screened Populations: The California Experience”. CF Diagnosis Consensus Conference, Phoenix, AZ, October 6 2015.

143. “Clinical Insights in Cystic Fibrosis: Treatment, Adherence and Infection Prevention”. Palm Beach Children’s Hospital, West Palm Beach, FL, October 22 2015.

144. “Nutritional status and lung disease in CF”. First CF Expert Conference, AMSA, Mexico City, Mexico, November 12 2015.

145. “Outcome differences between Hispanic and Caucasian populations with CF”. First CF Expert Conference, AMSA, Mexico City, Mexico, November 13 2015.

146. “Research Proposal: Defining disease risk for children identified by the California CF newborn screening”. 2016 California CF Consortium Conference, Carmel, CA, January 30 2016.

147. “A Breath of Fresh Care: Enhancing CF Care One Step at a Time”. Boise CF Center and Mountain-West CF Consortium meeting, Boise, ID, April 28 2016.

148. “Primary Ciliary Dyskinesia in children”. Meet the Experts session, American Thoracic Society Public Advisory Roundtable, San Francisco, CA, May 14 2016.

149. “Elastase Confers a High Risk for the Development of Bronchiolitis Obliterans Syndrome”. 2016 American Thoracic Society Conference, San Francisco, CA, May 17 2016.

150. “Longitudinal assessment of sweat chloride values among infants identified by newborn screening”. 39th European Cystic Fibrosis Conference, Basel, Switzerland, June 9 2016.

151. “Safety, Tolerability, and Pharmacodynamics of Combination Lumacaftor/Ivacaftor Therapy in Patients Aged 6 through 11 Years With CF Homozygous for the F508del-CFTR Mutation”. 39th European Cystic Fibrosis Conference, Basel, Switzerland, June 10 2016.

152. “Physiopathology of CF lung disease and therapeutic opportunities”. Argentinian Respiratory Society Cystic Fibrosis Workshop, Buenos Aires, Argentina, September 23 2016.

153. “Current concepts in CF pulmonary exacerbations management”. Argentinian Respiratory Society Cystic Fibrosis Workshop, Buenos Aires, Argentina, September 23 2016.

154. “The challenges of adherence to therapies in CF”. Argentinian Respiratory Society Cystic Fibrosis Workshop, Buenos Aires, Argentina, September 23 2016.

155. “Update on therapeutic advances in CF”. Argentinian Respiratory Society Cystic Fibrosis Workshop, Buenos Aires, Argentina, September 23 2016.

156. “Clinical Insights in Cystic Fibrosis: Evolving management strategies”. Children’s Hospital of Orange County Cystic Fibrosis Center, Orange, CA, September 27 2016.

157. “The Evolving Spectrum of Ciliopathies and Respiratory Disease”. Pediatric Grand Rounds, Children’s Hospital of Orange County, Orange, CA, September 28 2016.

158. “Advances in Modulator Therapies for Cystic Fibrosis”. Second CF Expert Conference, AMSA, Monterrey, Mexico, November 17 2015.

159. “Cystic Fibrosis Newborn Screening Research Progress in the Consortium and Future Directions”. 2017 California CF Consortium Conference, Carmel, CA, January 28 2017.

160. “Cystic Fibrosis in the Era of Genomic Medicine”. 5th Brazilian Cystic Fibrosis Congress, Curitiba, Brazil, April 6th 2017.

161. “Understanding the CF pulmonary Microbiome”. 5th Brazilian Cystic Fibrosis Congress, Curitiba, Brazil, April 6th 2017.

162. “Use of Lumacaftor/Ivacaftor in pediatric patients”. 5th Brazilian Cystic Fibrosis Congress, Curitiba, Brazil, April 6th 2017.

163. “Assessing Pulmonary Function in Children: Back to the Basics”. Warren J. Warwick Wemorial Lectureship, Department of Pediatrics Grand Rounds, University of Minnesota. Minneapolis, MN, May 31 2017.

164. “CFTR Modulation – Where We Are and Where We Are Headed”. Cystic Fibrosis Summit: Current Trends and Future Directions. Newark, NJ June 16 2017.

165. “Primary Ciliary Dyskinesia: from Phenotype to Genotype and Back”. Rare Pediatric Respiratory Disease: Science Shapes Precision Care. University of California San Diego, La Jolla, CA, July 7 2017.

166. “Cystic Fibrosis: The Current Lay of the Land”. Cystic Fibrosis Summit: Current Trends and Future Directions. San Francisco, CA September 23 2017.

167. “CFTR Modulation – Where We Are and Where We Are Headed”. Cystic Fibrosis Summit: Current Trends and Future Directions. San Francisco, CA September 23 2017.

168. “Autonomous sweat stimulation and sensing devices”. Point-of-Person Laboratory Developments. 2017 MedTech Conference, San Jose, CA September 26 2017.

169. “Current concepts on cystic fibrosis lung disease”. 2nd Annual Advancement in Respiratory Care Pediatric and Neonatal Application Conference. Madera, CA Spetember 30 2017.

170. “Pulmonary exacerbations in Cystic Fibrosis”. 45th Congress of the Argentinian Association of Respiratory Medicine (AAMR). Cordoba, Argentina October 6 2017.

171. “Physiopathology of Cystic Fibrosis lung disease”. 45th Congress of the Argentinian Association of Respiratory Medicine (AAMR). Cordoba, Argentina October 7 2017.

172. “Non-CF bronchiectasis in pediatric patients”. 45th Congress of the Argentinian Association of Respiratory Medicine (AAMR). Cordoba, Argentina October 7 2017.

173. “Update on therapeutic advances in cystic fibrosis”. 45th Congress of the Argentinian Association of Respiratory Medicine (AAMR). Cordoba, Argentina October 7 2017.

174. “Current concepts on *Pseudomonas* infections in cystic fibrosis”. 45th Congress of the Argentinian Association of Respiratory Medicine (AAMR). Cordoba, Argentina October 8 2017.

175. “The science of CFTR: Translating basic defect knowledge into therapies”. 31st North American Cystic Fibrosis Conference, Indianapolis, Indiana, November 1 2017.

176. “CF patient registry: Obejctives and expectations for Mexico”. CF summit 2018, Puerto Vallarta, Mexico February 18 2018.

177. “The Lung Clearance Index (LCI)”. LEAD (Lectures Education Awareness and Discussion), Buenos Aires, Argentina, July 12 2018.

178. “Clinical experience with the combination of correctors and potentiators of CFTR”. LEAD (Lectures Education Awareness and Discussion), Buenos Aires, Argentina, July 13 2018.

179. “Practical skills workshop: Application fo the Lung Clerance Index (LCI)”. LEAD (Lectures Education Awareness and Discussion), Buenos Aires, Argentina, July 13 2018.

180. “Early intervention for homozygous F508del pediatric patients”. XXXIX Brazilian Thoracic Society Conference, Goiania, Brazil August 7 2018.

181. “Cystic Fibrosis Update”. 2018 California Respiratory Care Practitoners Conference, Fresno, CA September 29 2018.

182. “New developments in the assessment of lung function in CF patients.” 32nd North American Cystic Fibrosis Conference, Denver, CO, October 20 2018.

183. “Innovative methodologies for the assessment of lung function in childen with cystic fibrosis”. 12th Pediatric Pulmonology Congress, Latin American

Society of Pediatric Pulmonology (SOLANEP), Punta Cana, Dominican Republic, November 8 2018.

184. "Bronchiectasis in children". 12th Pediatric Pulmonology Congress, Latin American Society of Pediatric Pulmonology (SOLANEP), Punta Cana, Dominican Republic, November 8 2018.

185. "Respiratory failure in cystic fibrosis". 12th Pediatric Pulmonology Congress, Latin American Society of Pediatric Pulmonology (SOLANEP), Punta Cana, Dominican Republic, November 8 2018.

186. "Oxygen therapy management in infants". 20th Pediatric Congress, Ecuador Pediatric Society, Quito, Ecuador, April 6 2019.

187. "Respiratory failure in Cystic Fibrosis". 20th Pediatric Congress, Ecuador Pediatric Society, Quito, Ecuador, April 6 2019.

188. "Innovative phenotyping and theratyping for infants with cystic fibrosis". Telethon Kids Institute Seminar Series, Perth, Australia, April 17 2019.

189. "Advances in the care of children with neuromuscular disorders". Grand Rounds, Perth Children's Hospital, University of Western Australia, Perth, Australia, April 18 2019.

190. "CFTR Modulators: Clinical experience and future prospects". Advances in Cystic Fibrosis, LEAD (Lectures Education Awareness and Discussion). Rio de Janeiro, Brazil, May 23 2019.

191. "Monitoring of lung function with the Lung Clearance Index (LCI)". Advances in Cystic Fibrosis, LEAD (Lectures Education Awareness and Discussion). Rio de Janeiro, Brazil, May 24 2019.

192. "Biomarkers of CF lung disease. Advances in Cystic Fibrosis". LEAD (Lectures Education Awareness and Discussion). Rio de Janeiro, Brazil, May 24 2019.

193. "Update on Cystic Fibrosis". 27th Annual Pediatric Update. Stanford, CA, July 18th 2019.

CURRENT RESEARCH ACTIVITIES

EXTRAMURAL SUPPORT - ACTIVE

1. “Defining the Clinical Utility of the Lung Clearance Index”. PI, Cystic Fibrosis Foundation.
    a. Project Period: 04/01/17-03/31/20

2. “Collaborative Research: A Non-invasive and Wearable Molecular Diagnostic Platform for Remote and Passive Monitoring of Patients at Risk for Sepsis”. Co-PI, NSF-NIH, Smart and Connected Health Program (SCH).
    a. Project Period: 08/01/2017 – 07/31/2020

3. “Innovative respiratory assessment for disease progression in children with Duchene's Muscular Dystrophy”. Co-PI, NHRMC, Australia.

4. “Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections”. PI, NHLBI, 1 R01 HL148184-01.

5. “Pf Bacteriophages in the Pathophysiology of Pseudomonas aeruginosa Infection in the CF airway”. Co-Inv. (P.I. Bollyky), CFF BOLLYK17G0.
    a. Project Period: 11/1/2017 – 10/31/2019

6. “Bacteriophage in the Pathophysiology of Cystic Fibrosis and Pseudomonas aeruginosa Infection”. Co-Inv. (P.I. Bollyky), NIH NHLBI 1R21AI137432.
    a. Project Period: 4/1/2018 – 3/31/2020

7. “Novel formulation and repurposing of small molecules to restore epithelial health in the cystic fibrosis airway”. Co-PI, Source: Stanford SPARK
    a. Project Period: 01/12/2017-01/11/2019

8. “Newborn Screening Cystic Fibrosis Center at Stanford”. Program Director. Source: State of California Department of Health (GDSP-08-CF012).
    a. Project Period: 07/01/17-06/30/20

9. “Translational CF Therapeutics Development Center at Stanford University”. PI. Source: Cystic Fibrosis Foundation (MILLA09Y0).
    a. Project Period: 01/01/18-12/31/18

10. “Cystic Fibrosis Center at Stanford”. Program Director. Source: Cystic Fibrosis Foundation (C011-09-166).
    a. Project Period: 07/01/18-06/30/19

11. “Genetic Disorders of Mucociliary Clearance”. Site PI (Overall PI: Michael Knowles, MD). Source: NIH (NHLBI 9U54HL096458-06).
    a. Project Period: 09/19/2014-07/31/2019

12. “G551D Observational Study (GOAL)”. Multicenter study, Site PI (Overall PI: Steven Rowe, MD, MSPH). Source: Cystic Fibrosis Foundation (GOAL-OB-11).

a. Project Period: 03/01/2012-12/31/2020

13. "Collection of CFTR Mutations for Laboratory Quality Assurance". Multicenter Study, Site PI (Overall PI: Martin Kharrazi, PhD.). Source: Sequoia Foundation.
    a. Project Period: 07/01/17-06/30/20

14. "OPTIMIZing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial." Site PI (PI: Bonnie Ramsey, MD). Source: NIH (NHLBI 1U01 HL114623).
    a. Project Period: 09/15/2013-06/30/2018

15. "Care innovation at the Stanford Cystic Fibrosis Center". PI. Source: Cystic Fibrosis Foundation (MILLA14PE0).
    a. Project Period: 08/01/2018 - 07/31/2019

EXTRAMURAL SUPPORT - PENDING

1. "Mechanistic Modeling and In-Vivo Validation of Analyte Pathways for Peripheral Biochemical Monitoring". Co-PI, Air Force Office of Scientic Reseacrh (AFOSR), #FA9550-19-S-003.

PATENTS

1. 15/700119. Autonomous Sweat Extraction and Analysis Using a Fully-Integrated Wearable Platform.

2. 62/855,667. Diagnosis of Cystic Fibrosis using Raman spectroscopy.

INDUSTRY SPONSORED CLINICAL RESEARCH

1. A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation. Multicenter Study, Site PI.
   Sponsor: Vertex Pharmaceuticals Inc.

2. A Phase 3, Rollover Study to Evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation. Multicenter Study, Site PI.
   Sponsor: Vertex Pharmaceuticals Inc.

3. A Phase 3, Open label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX 661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation. Multicenter Study, Site PI.
   Sponsor: Vertex Pharmaceuticals Inc.

4. A Multi-center, Randomized, Placebo-Controlled, Ascending Dose Phase I Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects with Cystic Fibrosis. Multicenter Study, Site PI.
   Sponsor: Proteostasis Therapeutics.

5. A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Multicenter Study, Site PI.
   Sponsor: Proteostasis Therapeutics.

6. A Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects with Primary Ciliary Dyskinesia. Multicenter Study, Site PI.
   Sponsor: Parion Sciences, Inc.

OTHER ACTIVITIES:

1. Expert Advisory Panel member to the NICHQ Breakthrough collaborative series project to improve outcomes in children with CF, (P.I.: Michael Schecter, Source: CF Foundation and NICHQ), 2002 – 2005.

2. Steering Committee Member, Cystic Fibrosis Foundation Therapeutics Development Network, 2002 – 2007.

3. Center Committee Member, Cystic Fibrosis Foundation, 2003 - 2011.

4. Accelerating Rate of Improvement in CF Care Leadership, Cystic Fibrosis Foundation, 2003 - 2010.

5. Member, Scientific Advisory Committee, University of Minnesota General Clinical Research Center, 2003 - 2006.

6. Special Review Panel for Microbiology Referral Centers, Cystic Fibrosis Foundation, May 2004.

7. Faculty of 1000 Medicine Project, Pediatric Respiratory Medicine Section Faculty member, 2004 – 2009.

8. Ad-Hoc Grant reviewer, Crohn's & Colitis Foundation of America, 2005.

9. Alternate Member, University of Minnesota Medical School Faculty Senate, 2005 - 2007.

10. Advisory Committee Member, Newborn Screening Program, Minnesota State Department of Health, 2005 – 2007.

11. Chair, Protocol Review Committee, Cystic Fibrosis Foundation Therapeutics Development Network, 2005 – 2009.

12. Cystic Fibrosis Foundation, Center Committee Task Force Member, November 2005.

13. Cystic Fibrosis Foundation, CF Pulmonary Exacerbations Consensus Conference Member, June 2006.

14. National Institutes of Health. NIDDK Special Emphasis Panel ZDK1 GRB-6 (J1): CF Research and Translational Core Centers (P30). January 2007.

15. Canadian Cystic Fibrosis Foundation, Research Subcommitte, External Grant Reviewer, 2007 – Ongoing.

16. American Heart Association. Grant Peer Review Committee; Lung, Resuscitation and Respiration Section, 2008 – 2011.

17. American Thoracic Society, ATS/ERS Joint Working Group on Infant/Preschool Lung Function. 2008 – Ongoing.

18. Admissions Review Panel, Stanford University Medical School. 2008 – Ongoing.

19. Translational Research Centers Steering Committee Member, Cystic Fibrosis Foundation Therapeutics Development Network, 2009 – 2012.

20. Chair, Student Research and House Officer Awards Selection Committee, Society for Pediatric Research, 2010 – 2012.

21. Clinical Advisor, Sweat Rate Research Consortium, Cystic fibrosis Foundation Therapeutics, Inc. 2009 – 2017.

22. European Confederation of Medical Mycology (ECMM) / International Society for Human and Animal Mycology (ISHAM) Working Group on Fungal Respiratory Infections in Cystic Fibrosis. 2009 – Ongoing.

23. Society for Pediatric Research, Respiratory Section abstract reviewer. 2009 – Ongoing.

24. Scientific Program Chair, California CF Consortium Annual Conference. 2010 – Ongoing.

25. Scientific Advisory Board member, Primary Ciliary Dyskinesia (PCD) Foundation. 2012 – Ongoing.

26. National Institutes of Health. NHLBI Special Emphasis Panel ZHL1 CSR-F S1 (R01): Early Cystic Fibrosis Lung Disease in Humans. June 2012.

27. National Institutes of Health. NHLBI Special Emphasis Panel ZHL1 CSR-S: S1 (UO1): Mechanisms of HIV-Related Lung Disease. July 2013**.**

28. Child Health Research Institute (CHRI) at Stanford University, Grant Review Committee member. March 2013 – Ongoing.

29. Co-Chair, Multiple Breath Washout for Cystic Fibrosis Consensus Committee; Cystic Fibrosis Foundation. June 2013 – June 2015.

30. National Institutes of Health. Medical Imaging Study Section, *ad-hoc* member. PA12-284: Exploratory/Developmental Bioengineering Research Grants (EBRG). February 13 2014**.**

31. Member, American Thoracic Society Project Committee: Standardization of Preschool Inert Gas Washout. May 2014 – Ongoing.

32. Co-Chair, Protocol Development and Review Committee; Succes with Therapies Research Consortium, Cystic Fibrosis Foundation. August 2014 – 2018.

33. National Institutes of Health. NHLBI Special Emphasis Panel ZDK1 GRB-7 (J2) 1: Cystic Fibrosis Research and Translation Core Centers (P30). November 2014.

34. Advisory Board Member; Clinical Research Fellowship Program, Lundbeck Foundation & The Ministry of Higher Education and Science, Conpenhagen, Denmark. October 2014 – Ongoing.

35. Member and California Representative, US CF Newborn Screening Quality Improvement Consortium. October 2014 – Ongoing.

36. Member, American Thoracic Society Project Committee: Primary Ciliary Dyskinesia. January 2015 – Ongoing.

37. Member, Cystic Fibosis Foundation Diagnostic Consensus Working Group. June 2015 – Ongoing.

38. Steering Committee Member, Cystic Fibrosis Foundation Therapeutics Development Network, 2016 – 2019.

39. National Institutes of Health. NIH Special Emphasis Panel ZRG1 MOSS-C (02):. 2016.

40. National Institutes of Health. NIH Special Emphasis Panel 08 ZRG1 PSE-V 2017.

41. Federal Food and Drug Administartion (FDA), Office of Orphan Products, Development Grant review panel, FY 2018.

42. Appointments and Promotions Committee, Stanford University School of Medicine. Dec 2017 – Ongoing.

43. Member, Research Advisory Committee, Department of Pediatrics, Stanford University School of Medicine. 2019 – Ongoing.

44. National Institutes of Health. NIH Special Emphasis Panel ZRG1 CVRS-A(11) Small Business Review Respiratory Sciences. 2019.

45. Steering Committee Member; Success with Therapies Research Consortium, Cystic Fibrosis Foundation. August 2019 – Ongoing.